22 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Altra ricerca

Age-linked biological context shapes adaptive immunity in Alzheimer's disease.

Sophie Shirenova, Arya Biragyn, Eitan Okun

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

Abstract originale

Alzheimer's disease (AD) is increasingly recognized as a neuroimmune disorder with protective or pathogenic adaptive immunity dependent on the biological context. This review synthesizes evidence from human studies, genetic analyses, mouse models, and clinical trials to examine how lymphocytes and humoral immunity influence AD. Human studies show T-cell accumulation in disease-relevant brain compartments, peripheral B-cell remodeling, endogenous anti-amyloid beta antibodies, and cytokine dysregulation. Complementary genetic studies implicate antigen presentation, lymphocyte regulation, immunoglobulin signaling, and immune checkpoints in AD susceptibility. The findings indicate that the consequences of adaptive immune engagement vary with age and disease stage and are further modified by sex, genetic context, and therapeutic modality. Adaptive immunity in AD is therefore dynamic rather than uniformly beneficial or detrimental. Age in particular emerges as a major determinant that biases immune responses from earlier regulatory states toward later maladaptive inflammation, providing a framework to reconcile conflicting findings and guide stage-aware immunomodulation.

Parole chiave

Alzheimer DiseaseHumansAdaptive ImmunityAnimalsAgingBrainT-LymphocytesAlzheimer's diseaseB cellsT cellsadaptive immunityagingneuroinflammation
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Age‐linked biological context shapes adaptive immunity in Alzheimer's disease SHIRENOVA et al.

Abstract

Alzheimer's disease (AD) is increasingly recognized as a neuroimmune disorder with protective or pathogenic adaptive immunity dependent on the biological context. This review synthesizes evidence from human studies, genetic analyses, mouse models, and clinical trials to examine how lymphocytes and humoral immunity influence AD. Human studies show T‐cell accumulation in disease‐relevant brain compartments, peripheral B‐cell remodeling, endogenous anti‐amyloid beta antibodies, and cytokine dysregulation. Complementary genetic studies implicate antigen presentation, lymphocyte regulation, immunoglobulin signaling, and immune checkpoints in AD susceptibility. The findings indicate that the consequences of adaptive immune engagement vary with age and disease stage and are further modified by sex, genetic context, and therapeutic modality. Adaptive immunity in AD is therefore dynamic rather than uniformly beneficial or detrimental. Age in particular emerges as a major determinant that biases immune responses from earlier regulatory states toward later maladaptive inflammation, providing a framework to reconcile conflicting findings and guide stage‐aware immunomodulation.

Highlights

Adaptive immunity in AD is dynamic rather than uniformly protective or pathogenic.

Age and disease stage provide a unifying framework for interpreting adaptive immune responses.

Genetic, human, and experimental evidence converges on adaptive immunity as a driver of AD.

Future immunotherapies should be stage‐specific, cell‐targeted, and biologically stratified.

1INTRODUCTION

Alzheimer's disease (AD) remains the leading cause of dementia in older adults and one of the greatest global public health challenges of the 21st century. As of 2025, an estimated 59 million individuals worldwide are living with dementia, of whom ∼60% to 70% are diagnosed with AD. The global prevalence of dementia is expected to rise in parallel with population aging and increased life expectancy.1 Clinically, AD is defined by progressive cognitive decline, memory impairment, and loss of functional independence. Pathologically, AD is characterized by systemic2 and central3 inflammation, synaptic dysfunction,4 oligomerization of monomeric peptides, plaques, and fibrils,5 extracellular deposition of amyloid beta (Aβ), and intracellular accumulation of hyperphosphorylated tau into neurofibrillary tangles, leading to neuronal loss.6 Despite these established hallmarks, the mechanisms driving Aβ and tau accumulation and the resulting neurodegeneration remain unclear. Clarifying how immune processes intersect with these core pathological events is therefore essential to understanding AD progression.

While innate immunity, particularly microglia (the resident myeloid cells of the central nervous system [CNS]), has attracted the most attention, recent findings emphasize the importance of adaptive immunity in both promoting and protecting against AD. Brain‐derived antigens drain via the glymphatic‐meningeal lymphatic systems into cervical lymph nodes (cLNs), where they are presented to adaptive immune cells, such as T and B cells.7, 8 Activated adaptive immune cells infiltrate sites of inflammation in the brain and modulate the activity of microglia, oligodendrocytes, and neurons. Complementing these mechanistic observations, genome‐wide association studies (GWASs) implicate adaptive immunity in AD by identifying risk loci within genes that regulate immune functions, including antigen presentation, T‐cell function, and immunoglobulin (Ig) activity.9, 10 Together, these findings support adaptive immunity as an active component of AD pathogenesis, yet its precise role in disease initiation and progression remains unresolved.

Adaptive immunity is mediated primarily by antigen‐specific T and B lymphocytes, which generate targeted and memory responses. Immune‐based intervention strategies have become a major focus of therapeutic development and experimental investigation in AD. Clinical trials designed to modulate these pathways have produced conflicting outcomes, with some studies reporting clinical or biomarker improvement11, 12 and others demonstrating limited efficacy or treatment‐related adverse effects.13, 14 Although these studies show that immune intervention is feasible in AD, conflicting outcomes may reflect pathogenic adaptive immune activation shaped by treatment modality, disease stage, biological age, and genetic risk. These divergent outcomes are mirrored in preclinical AD studies, where manipulation of adaptive immune components in transgenic mouse models, through genetic deficiencies or antibody‐mediated depletion, attenuates amyloid pathology at later stages of the disease,15, 16, 17 whereas similar interventions exacerbate amyloid deposition or accelerate disease progression when applied at early stages or in younger animals.18, 19, 20, 21 Together with the heterogeneous outcomes observed in clinical trials, these findings indicate that the effects of adaptive immune modulation in AD are highly context‐dependent. This raises a central unresolved question: Under what pathophysiological conditions does adaptive immunity confer protective rather than pathogenic effects in AD?

Emerging evidence indicates that biological age is a critical determinant of whether adaptive immune responses mitigate or amplify neurodegeneration across disease stages.15, 21, 22, 23 Adaptive immune cells change both phenotypically and functionally during aging, accumulating T and B cells exhibiting chronically activated, exhausted, and/or immunosenescent features that are not present or rarely found in young hosts.24, 25, 26 However, the cellular and temporal dynamics of B‐ and T‐cell activity throughout AD progression remain poorly understood, limiting our ability to define how disease stage and individual patient factors influence these outcomes. These observations support the hypothesis that the role of adaptive immunity in AD is not fixed but varies with age, disease stage, and genetic background.

Untangling context‐dependent immune effects in patients remains challenging because most human studies capture disease near symptom onset and are confounded by heterogeneity in genetic background, immune status, and comorbidities. To overcome these limitations, preclinical early‐onset AD (EOAD) models carrying amyloid precursor protein (APP), presenilin‐1 (PS1), or presenilin‐2 (PS2) mutations provide a controlled framework for examining immune‐brain interactions across defined pathological stages. These models reveal strain‐, sex‐, and age‐specific differences in adaptive immune cell infiltration, Ig deposition, and microglial interactions,20, 21, 22, 23 offering mechanistic insight into the conditions under which adaptive immunity becomes protective or pathogenic.

In this review, we integrate evidence from human studies, genetic analyses, mechanistic mouse models, and clinical immunotherapy trials to examine how adaptive immunity shapes AD development and progression. We argue that age and disease stage provide the most consistent framework for reconciling apparently contradictory findings, while sex, genetic context, and syndrome‐specific states, such as Down syndrome (DS), further modify adaptive immune behavior. EOAD‐like mouse models are discussed not as the sole disease frame but as mechanistic systems that reveal when adaptive immunity supports surveillance and clearance and when it shifts toward maladaptive inflammation.

2HUMAN EVIDENCE AND CONCEPTUAL BASIS FOR ADAPTIVE IMMUNITY IN AD

Human studies provide evidence that adaptive immunity is altered throughout AD and offer a conceptual framework for understanding how these changes may contribute to disease pathogenesis.

2.1Age‐driven remodeling of adaptive immunity

The adaptive immune system evolves throughout life, acquiring memory for antigens and responding with increasing affinity and kinetics upon re‐exposure. During aging, adaptive immune cells undergo phenotypic and functional changes that can impair immune competence, which may contribute to AD pathogenesis.27 Aging shapes both composition and responses of the innate and the adaptive immune systems, leading to the accumulation of antigen‐experienced B‐ and T‐cell subsets, including age‐associated B cells (ABCs),24 pathogenic insulin resistance‐inducing B cells (4BL cells),25 and a distinct CD8+ T‐cell subset (DP8 cells) co‐expressing the ectonucleotidases CD39 and CD73.26 Aging drives a shift in T‐helper (Th) CD4+ and cytotoxic CD8+ T cells from naïve phenotypes toward effector‐memory states, characterized by heightened activation and increased expression of interferon‐gamma (IFN‐γ), tumor necrosis factor‐alpha (TNF‐α), and cytotoxic molecules. These age‐associated changes are evident across multiple tissues, including the spleen and peripheral blood in both humans and mice.28, 29, 30 Aging is also characterized by a chronic, systemic, low‐grade inflammatory state, termed inflammaging.31 Inflammaging affects multiple physiological systems, including the adaptive immune compartment, and creates a peripheral environment that can influence CNS homeostasis.31 Importantly, such age‐related remodeling may also extend to antigen‐specific adaptive immune responses during neurodegenerative disease. In Parkinson's disease, α‐synuclein‐specific T‐cell responses have been identified and were subsequently shown to peak during the preclinical and early symptomatic stages before declining with disease progression.32, 33 Although observed in a distinct neurodegenerative disorder, this temporal pattern provides independent evidence that antigen‐specific adaptive immune responses can evolve across disease stages.

2.2Glymphatic antigen drainage to peripheral immunity

In neurodegenerative proteinopathies, a group of disorders characterized by abnormal protein accumulation or misfolding in tissues (e.g., AD, Parkinson's disease, and frontotemporal dementia), pathological antigens originating in the brain are thought to drain via the glymphatic system.34, 35 The glymphatic system is a proposed clearance pathway through which interstitial fluid and cerebrospinal fluid (CSF) exchange, facilitating the transfer of brain‐derived proteins to the meningeal lymphatic vessels and eventually to the deep cLNs (dcLNs).8, 36 In AD, these brain‐derived proteins include toxic Aβ and pathological tau species, which disrupt cellular homeostasis and drive neurodegeneration. In addition to drainage toward the cervical lymph nodes, immune surveillance of CNS‐derived signals also occurs locally at the brain borders. The dural sinuses function as neuroimmune interfaces where CNS‐derived antigens can be sampled by resident immune cells, while skull bone marrow provides a local source of immune cells that can access the meninges through specialized vascular channels.37, 38 Within the dcLNs, adaptive immune cells interact with antigen‐presenting cells (APCs), including dendritic cells and B cells, which display brain‐derived peptides to naïve CD4+ and CD8+ T cells, thereby triggering their activation.39 Following antigen exposure, B cells, acting as Ig producers, cytokine producers, and APCs, undergo clonal expansion along with activated T cells to promote a coordinated adaptive immune response.40 Through this pathway, adaptive immunity can continuously survey CNS‐derived antigens and mount antigen‐specific responses. Evidence from human AD patients indicates that Aβ‐containing cells are present in the dcLNs and are absent in the inguinal LNs.41, 42

2.3T‐cell infiltration, clonal expansion, and antigen recognition in human AD

T cells are not randomly distributed in the AD brain but are localized to anatomically and pathologically relevant regions. This pattern is supported by the increased number of CD3+ T cells seen in the brains of human AD patients, which is significantly higher than in other neurodegenerative disorders.43, 44 Among these, infiltrating CD8+ T cells were observed in the hippocampus, middle temporal gyrus, perivascular spaces, and leptomeninges.45, 46, 47 Adaptive immune cells were also found adjacent to Aβ plaques and phosphorylated tau tangles, in the brain parenchyma of both human patients and mouse models.15, 20, 45, 48, 49 In a separate analysis, CD8+ T cells were identified clustered around hippocampal perivascular spaces affected by cerebral amyloid angiopathy (CAA).46 The heightened T‐cell infiltration in CAA‐affected vessels may reflect entry through vascular breaches rather than a response to Aβ itself. Because tau pathology was not assessed in that study, it remains unclear whether T cells in these regions are more strongly associated with Aβ or tau pathology.

Quantitative analyses further refine this association. In human brain tissue, CD3+ T cells were significantly more abundant in the frontal gyrus of individuals with Braak stage VI, characterized by extensive neocortical tau pathology, than those with preclinical Braak stages I to II, in which neurofibrillary tangles are confined mainly to the transentorhinal/entorhinal cortex.50, 51 These findings are consistent with recent evidence indicating that T‐cell infiltration is more pronounced in brains affected by tau pathology, in both human AD and experimental tauopathy models, supporting a particularly strong association between T‐cell accumulation and tau‐associated neurodegeneration.52 Importantly, in the PS19 tauopathy model, T‐cell depletion reduced neuroinflammation, brain atrophy, and cognitive impairment, providing direct evidence that infiltrating T cells can contribute causally to tau‐associated neurodegeneration.51 Similarly, a positive correlation was found between CD3+ T‐cell numbers and tau burden in non‐immunized AD patients, independently of Aβ42, microglial markers, or complement C1q.53 These data collectively suggest a tighter relationship between T‐cell accumulation and tau pathology than with amyloid deposition.

A clonal T‐cell response is also evident, characterized by the expansion of T‐effector memory CD45RA+ CD8+ T cells (termed TEMRA).47 These highly differentiated cytotoxic T cells expand during aging and chronic inflammation and are enriched in AD. As late‐stage senescent cells, TEMRA cells can exhibit heightened cytotoxicity and increased IFN‐γ production.46, 54 Notably, the antigen specificity of these T‐cell responses remains incompletely defined, although Aβ‐reactive T cells have been detected in humans and were more frequent in older individuals and patients with AD than in middle‐aged controls.55 Evidence from in vitro studies further refines this question, showing that CD4+ and CD8+ T cells respond to the C‐terminus and mid regions, but not to the N‐terminus of the Aβ or tau peptides.54 The reason for this selective epitope responsiveness remains unknown. However, peptide reactivity alone does not demonstrate that these epitopes drive the dominant clonal expansions observed in vivo. Consistent with this, T‐cell receptor (TCR) analysis in AD patients failed to identify Aβ‐specific clones and instead detected Epstein‐Barr virus‐specific CD8+ TCRs.46 These findings suggest that antigen specificity in AD may extend beyond classical amyloid‐directed recognition and could reflect a more complex interaction with pathogen‐derived antigens.46 Thus, although T cells accumulate and clonally expand in AD, the precise antigenic drivers of this response remain unresolved.

2.4Peripheral B‐cell remodeling and antibody responses in human AD

Compared with T cells, B cells are rarely detected in the brain of AD patients and are typically localized to the meninges, perivascular spaces, draining dcLNs, and circulation rather than the brain parenchyma.48 Despite this limited parenchymal presence, evidence indicates that B cells have an active role in AD pathology. Whereas healthy aging is characterized by a decline in peripheral B‐cell numbers, patients with AD do not exhibit this reduction.49 Moreover, increased Aβ plaque load was associated with elevated peripheral B‐cell counts, but not with T‐ or natural killer (NK)‐cell counts. These observations suggest that B‐cell alterations in AD reflect disease burden rather than normal aging.

Transcriptomic analyses revealed altered expression of B‐cell‐specific pathways in AD, including genes linked to lineage commitment, isotype switching, and circulating Ig complexes.49 These analyses further reveal upregulation of interleukin (IL)‐10 and recombination activating gene 2 (RAG2), indicating chronic activation and ongoing receptor recombination, alongside reduced expression of forkhead box P3 (FOXP3) and replication timing regulatory factor 1 (RIF1), suggesting impaired regulatory signaling. Differential expression of polymeric Ig receptor (PIGR) further reflects altered antibody transport pathways,49 as PIGR mediates the transcytosis of polymeric Igs (e.g., IgA and IgM) across epithelial and barrier tissues, implying that its dysregulation may disrupt Ig trafficking between peripheral compartments and barrier interfaces, including those relevant to CNS immune surveillance.

These observations suggest that in AD, B cells are numerically altered and undergo transcriptional reprogramming that changes their cytokine output, receptor recombination, regulatory potential, and antibody transport. Early in the disease, this may enhance beneficial antibody‐mediated microglial clearance of Aβ. However, chronic dysregulation, characterized by excess IL‐10, reduced regulatory FOXP3+ cells, possible autoreactivity driven by RAG2 activity, and impaired antibody transport due to altered PIGR expression, could shift B cells toward pathogenic roles, amplifying dysfunction rather than promoting homeostasis. This proposed temporal shift reflects the broader transition from protective surveillance to maladaptive amplification proposed for adaptive immunity in AD.

Consistent with this functional duality, B‐cell‐derived Igs have been shown to modulate microglial activity by enhancing Aβ phagocytosis during acute exposure but promoting microglial dysfunction and increased Aβ accumulation under chronic stimulation.49 As a result, AD patients spontaneously develop anti‐Aβ antibodies or exhibit increased numbers of B cells producing anti‐Aβ antibodies.56 Thus, antibody production in AD appears to reflect both adaptive engagement and dysregulation that may occur with chronic exposure.

This pattern may also be influenced by age‐related changes in the B‐cell compartment. ABCs are antigen‐experienced autoreactive B cells characterized as B220+CD19+Tbet+CD11c+CD21−CD23−CD95−CD43− and accumulate with aging in various tissues, including the meninges.24, 57 ABCs require constitutive B‐cell receptor (BCR) activation, such as chronic exposure to self‐antigens in autoimmune conditions. This raises the hypothesis that the B‐cell response in AD could reflect ABCs reacting to Aβ, following constant Aβ drainage to the meninges and dcLNs, thereby integrating an additional aging‐dependent mechanism into AD pathogenesis.58 If so, B‐cell activation in AD may represent an intersection between chronic antigen exposure and age‐dependent immune remodeling.

2.5Microglia‐adaptive immunity crosstalk

Within the brain, microglial cells serve as myeloid sentinels that continuously survey their surroundings and rapidly shift their transcriptional programs in response to sensed perturbations.59 A central regulator of these microglial responses is triggering receptor expressed on myeloid cells 2 (TREM2), an AD risk gene that regulates microglial survival, metabolism, phagocytosis, and the transition toward disease‐associated activation states.60 Through these effects, TREM2 can shape the inflammatory and antigen‐presenting environment encountered by infiltrating lymphocytes, thereby providing an important mechanistic link between AD‐associated microglial states and adaptive immune responses. Because Aβ is neurotoxic, microglia initially respond by attempting to clear it through phagocytosis and enzymatic degradation.59 Under acute activation, this response is adaptive and effective, reducing Aβ burden. However, chronic or sustained stimulation drives microglia into a disease‐associated state characterized by maladaptive pro‐inflammatory signaling.61 In this state, microglia exhibit diminished capacity to clear Aβ and instead amplify local inflammatory cascades, exacerbating neuronal stress and tissue injury.59, 61

Another source of microglial activation is the secretion of pro‐inflammatory cytokines, such as IFN‐γ, by infiltrating T cells,62 which in the aged brain is predominantly produced by CD8+ T cells and, to a lesser extent, by effector CD4+ T cells, thereby altering the microglial phenotypic state and function,54, 63, 64 although the direct mechanistic interplay between IFN‐γ‐producing T cells and microglia in the context of AD remains to be fully defined.65 Beyond IFN‐γ, IL‐17‐producing γδ T cells may represent an additional T‐cell‐mediated pathway contributing to early dysfunction in AD. In female 3xTg‐AD mice, IL‐17‐producing cells, predominantly γδ T cells, accumulated in the brain and meninges concomitantly with the onset of cognitive decline, while intracerebroventricular IL‐17 neutralization prevented early deficits in short‐term memory and synaptic plasticity.66 Notably, these effects preceded blood–brain barrier (BBB) disruption and detectable Aβ or tau pathology, suggesting that meningeal γδ T‐cell‐associated IL‐17 signaling can contribute to early functional impairment before established protein deposition. Together, inflammaging and age‐altered adaptive immune activity create a pro‐inflammatory landscape that shapes microglial responses and contributes to the escalating neuroimmune dysfunction characteristic of AD.31, 59, 61, 65

Whereas studies utilizing mouse models of amyloidosis report Aβ‐reactive CD8+ T cells infiltrating the brain following immunization,17 it remains unclear whether Aβ, tau pathology, or broader inflammatory cues drive the recruitment of these T cells to the brain in AD patients. Resolving these questions will be essential to defining how adaptive immune signals influence microglial dysfunction and disease progression in AD.

3GENETIC EVIDENCE SUPPORTING ADAPTIVE IMMUNE INVOLVEMENT IN AD

While most human genetic evidence derives from late‐onset AD (LOAD) cohorts, these studies implicate antigen presentation, lymphocyte regulation, and Ig‐related pathways in AD susceptibility. The strongest support for adaptive immune involvement comes from genome‐wide association studies of LOAD.

3.1GWAS‐based evidence for adaptive immune pathway involvement in AD

Although EOAD is primarily linked to rare mutations in APP, presenilin (PSEN)1, or PSEN2, GWASs of LOAD have identified more than 130 risk loci,9 with key enriched loci in innate and adaptive immune pathways9, 10, 67 (Table 1, Figure 1).

The strongest genetic risk factor for LOAD remains the apolipoprotein E (APOE) ε4 allele, which affects Aβ clearance, lipid metabolism, synaptic signaling, mitochondrial homeostasis, and immune responses.9, 10, 70 With respect to immune function, APOE ε4 has been linked to microglial activation,71 immunosuppression of IL‐17+ neutrophils,72 lipid‐metabolism disturbances, and BBB dysfunction, which together promote T‐cell infiltration to the brain.73

Beyond APOE, GWASs have identified several loci that further strengthen the link between adaptive immunity and AD.10 One of the most prominent is human leukocyte antigen class II DR beta 1 (HLA‐DRB1), which encodes a major histocompatibility complex class II (MHC‐II) molecule expressed on APCs. Genetic associations involving both risk‐associated and protective HLA‐DRB1 alleles further implicate MHC‐II‐mediated antigen presentation in AD susceptibility and disease modification, potentially by reshaping CD4+ T‐cell activation against CNS‐derived antigens.9, 52

Another key locus is the spi‐1 proto‐oncogene (SPI1, also termed PU.1), a transcription factor involved in myeloid and lymphoid development, including APCs.74
SPI1 regulates immune genes involved in antigen presentation and T‐cell priming. Reduced expression of SPI1 has been linked to delayed AD onset and lower disease risk,9, 74 potentially through reduced microglial activation and inflammatory signaling.

Additional AD‐associated loci summarized in Table 1 and Figure 1, including PLCG2, INPP5D, HLA‐DQA1, LILRB2, TNIP1, CR1, CLU, and ABI3, converge on immune‐receptor signaling, complement regulation, antigen handling, and immune‐cell activation.67, 68, 69, 75, 76, 77, 78, 79 Although several of these genes have prominent functions in myeloid cells, the pathways they regulate also shape the broader immune environment in which adaptive immune responses develop.

3.2Immune regulatory mechanisms associated with AD risk

Leukocyte Ig‐like receptor genes, including LILRB2 and LILRB4, are associated with LOAD and regulate activation thresholds in myeloid and lymphoid cells.10, 80, 81 Notably, LILRB2 has been shown to interact with Aβ in mouse models, and antibody‐mediated inhibition reduces amyloid burden, linking immune inhibitory signaling to amyloid pathology.82 Another GWAS locus, TNF‐α‐induced protein 3 interacting protein (TNIP1), encodes a negative regulator of nuclear factor kappa B signaling.83 Through this pathway, TNIP1 may shape the inflammatory environment that influences antigen presentation and adaptive immune responses.84

Genetic evidence also implicates immune checkpoint regulation in AD susceptibility. Hepatitis A virus cellular receptor 2 (HAVCR2), also known as T‐cell Ig and mucin‐domain containing‐3 (TIM‐3), encodes an inhibitory receptor expressed on both T cells and microglia.85 TIM‐3 regulates T‐cell exhaustion and peripheral tolerance and in the CNS also modulates microglial activation. In microglia, TIM‐3 signaling suppresses pro‐inflammatory responses while concurrently limiting phagocytic and antigen‐presenting capacity. Conversely, altered TIM‐3 expression in LOAD brains suggests dysregulated checkpoint control, which may either reinforce maladaptive immune suppression or impair the resolution of chronic neuroinflammation.10, 85

Complement signaling further integrates innate and adaptive immune pathways in AD. Specifically, complement receptor 1 (CR1) binds complement‐opsonized targets such as C3b‐ or C4b‐tagged Aβ aggregates, thereby promoting their recognition and clearance by phagocytic cells, including microglia and peripheral myeloid cells. CR1‐mediated uptake of complement‐coated antigens may also facilitate MHC‐II loading and CD4+ T‐cell priming, linking amyloid clearance to adaptive immune activation. Thus, CR1 risk variants associated with AD may disrupt the balance between efficient opsonization‐driven clearance and controlled immune activation.9, 86

This genetic evidence points to an integrated immune circuit in AD, linking complement activation, antigen handling, MHC‐II‐mediated presentation, T‐cell priming, checkpoint regulation, and microglial inflammatory state (Table 1). Rather than implicating isolated immune pathways, these findings indicate that genetic variation may shift the balance between protective clearance and chronic neuroinflammation.

4EVIDENCE FROM EOAD MOUSE MODELS FOR ADAPTIVE IMMUNE INVOLVEMENT IN AD

Most causal insights into adaptive immunity in AD have emerged from EOAD‐like transgenic and knock‐in mouse models. Although these models incompletely recapitulate the full human disease spectrum, particularly tau‐dominant and late‐life features, they remain indispensable for defining how lymphocytes, antibodies, and microglia interact across disease progression.

4.1Mutation landscape and timeline of pathophysiological changes in EOAD mouse strains

While recently developed mouse models better recapitulate familial EOAD in humans by incorporating both Aβ and tau pathologies (see comprehensive review87), their use in studies of adaptive immunity remains limited. Most investigations of adaptive immune involvement have therefore relied on first‐generation EOAD mouse models, which predominantly feature Aβ pathology with minimal or no tau involvement. This raises a broader consideration regarding how the absence of extensive tau pathology might shape the T‐cell phenotypes observed in these models, particularly when compared with the more complex, stage‐dependent immune signatures observed in human AD. Thus, the central question is whether immune phenotypes defined in Aβ‐dominant systems fully capture the adaptive immune dynamics of human disease.

Despite their limitations, first‐generation models have been instrumental in uncovering fundamental aspects of adaptive and innate immune responses in AD. Although some of the discussed models were extensively reviewed elsewhere,87, 88, 89 here, we briefly outline only the features most relevant to interpreting adaptive immune findings: pathological tempo, promoter context, Aβ/tau involvement, and timing of neuroinflammatory change (Table 2, Figure 2). For an overview of findings in mouse models that develop tau pathologies, see.90

4.1.15xFAD: Rapid Aβ accumulation and early neuroimmune activation

The five familial AD mutations (5xFAD) mice develop rapid and aggressive Aβ pathology, with early plaque formation followed by gliosis and behavioral impairment45, 91 (Table 2, Figure 2). This compressed disease course makes the model useful for studying early neuroimmune activation and adaptive immune recruitment during Aβ‐driven pathology. However, this model predominantly reflects Aβ‐driven pathology with minimal tau involvement, which may limit its ability to capture the more complex, stage‐dependent immune dynamics observed in human AD.

4.1.2APP/PS1L166P: early plaque deposition with delayed functional decline

APP/PS1L166P mice92 exhibit early cortical Aβ deposition and microglial activation, making them useful for examining immune responses during the initial stages of plaque‐associated pathology (Table 2, Figure 2). Yet, functional decline occurs later, which may complicate temporal alignment between amyloid pathology, immune activation, and neurodegeneration.93, 94

4.1.3APP/PS1ΔE9: gradual Aβ accumulation with region‐specific neurodegeneration

APPswe/PS1ΔE9 mice95 show a slower progression of Aβ deposition and gliosis than 5xFAD mice, allowing immune responses to be examined across a more gradual pathological trajectory96, 97, 98, 99, 100 (Table 2, Figure 2). Nevertheless, this model shows region‐specific and incomplete neurodegeneration, which may limit its ability to fully capture neurodegenerative progression in human AD.101, 102, 103

4.1.4APPNL‐G‐F: physiological Aβ expression with gradual functional impairment

APPNL‐G‐F mice104 avoid artifacts related to hAPP overexpression by introducing AD‐linked mutations into the endogenous APP locus. This model develops gradual Aβ pathology and later neuroinflammatory changes, providing a useful system for studying immune responses under more physiological APP expression105, 106 (Table 2, Figure 2). However, the timing of neurodegeneration is not clearly defined.104, 105, 106, 107

4.1.53xTg‐AD: sequential Aβ and tau pathology

3xTg‐AD mice108, 109, 110 incorporate both Aβ‐ and tau‐related pathology, making them valuable for examining adaptive immune responses in a model that includes both major AD hallmarks (Table 2, Figure 2). Yet the delayed onset of tau pathology relative to early Aβ accumulation may complicate the interpretation of stage‐specific immune responses across disease progression.109, 111, 112, 113

In addition to the mutation profile, promoter context, such as Thy1, PrP, or endogenous knock‐in expression, critically influences the spatial distribution, expression level, and temporal kinetics of the pathology. Although these strains broadly converge on increased Aβ production, they differ substantially in the timing and severity of downstream pathological features, including intracellular and extracellular Aβ accumulation, plaque formation, microgliosis and astrogliosis, synaptic and long‐term potentiation deficits, neuronal loss, behavioral impairment, and immune landscape. This variability reflects multiple factors, including differences in genetic background, transgene expression levels, promoter specificity, methodological approaches, and, critically, the age at intervention and assessment. Accordingly, conclusions regarding AD mechanisms and immune dynamics require careful cross‐model interpretation rather than direct extrapolation.

4.2Characteristics of adaptive immune response in EOAD mouse models

Understanding the adaptive immune landscape in EOAD mouse models requires dissecting the complex interactions among immune cells at the interface between CNS and peripheral tissues. Although growing evidence implicates adaptive immunity in AD progression, systematic, age‐resolved characterization of adaptive immune responses across EOAD mouse models remains limited, which constrains cross‐model comparisons. This gap complicates the interpretation of model‐specific immune signatures and their translational relevance to human AD. In this section, we synthesize the current state of the art to provide an updated framework for identifying strain‐, mutation‐, and age‐dependent factors that may shape adaptive immune responses and influence the outcome of immune‐targeted interventions.

Among first‐generation models, 5xFAD mice exhibit pronounced yet partially conflicting alterations in adaptive immunity, particularly in the meninges and brain parenchyma. For example, aged male 5xFAD mice (13 to 14 months old) exhibit reduced lymphatic coverage along the dural sinuses, accompanied by increased numbers of T and B cells in the surrounding tissues.35 In contrast, 10‐month‐old male and female 5xFAD mice also exhibit decreased counts of both CD4+ and CD8+ T cells in the dural meninges, whereas peripheral organs such as the spleen, lungs, and liver show no significant differences.21 These divergent findings highlight potential age‐, sex‐, or methodological dependencies in meningeal immune assessments. Beyond the meninges, the 5xFAD strain also exhibits T‐cell infiltration into the brain parenchyma as early as 6 months of age, with further accumulation at 921 and 12 months,114 indicating progressive CNS immune recruitment over time.

Other EOAD models also show CNS T‐cell accumulation. APPswe/PS1ΔE9 mice show increased hippocampal T cells by 12 to 13 months of age.22, 115 In contrast, APPNL‐G‐F mice exhibit an earlier onset of T‐cell accumulation, starting at 3 months,21 indicating potentially model‐specific immune kinetics linked to differences in transgene expression, Aβ burden, or antigen presentation.

Unlike the predominantly infiltration‐driven patterns observed in other models, 3xTg‐AD mice exhibit peripheral and central signatures of adaptive immune activation, with minimal early CNS infiltration. These include elevated serum and cortical IgG, increased plasma cells in the spleen and bone marrow, and a Th17‐skewed T‐cell profile in blood and lymphoid tissues.116 The absence of brain parenchymal T cells at 3 to 4 months117 suggests delayed or restricted CNS immune recruitment in this model.

Thus, adaptive immune engagement is common to EOAD mouse models; however, the timing, anatomical distribution, and qualitative nature of these responses are tightly coupled to strain‐specific mutation profiles and disease kinetics, indicating that immune phenotypes cannot be interpreted independently of pathological context.

4.3Functional implication of depleting adaptive immune cells in EOAD mouse models

If adaptive immunity actively shapes EOAD pathology, then manipulating its function is expected to yield predictable outcomes. Yet, experimental literature reveals that this is not always the case. Various methodological approaches, including genetic manipulation and antibody‐mediated depletion of T and/or B cells, were used to evaluate the impact of adaptive immune cells on Aβ pathology and cognitive function (Table 3, Figure 3). While some studies report exacerbation of pathology following T‐ and B‐cell depletion,18, 19, 20, 21 others demonstrate potential neuroprotective effects.15, 16, 17 This conflicting response suggests that adaptive immune cells are neither uniformly protective nor uniformly pathogenic. Instead, their role is likely influenced by various factors, including mutation profile, age and disease stage, and tissue compartment.

Further complicating interpretation, sex‐specific effects remain insufficiently resolved. Experimental designs vary considerably, as some studies employ mixed‐sex cohorts,16, 18, 20, 23, 118, 124 other studies restrict analysis to one sex,15, 17, 123 and still others do not report sex at all (Table 3).19, 122 The absence of direct statistical comparisons between male and female responses to immune modulation further limits the interpretation of sex‐specific effects of adaptive immune targeting. While mutation context and experimental design contribute to variability, the age at which immune manipulation is performed may represent a dominant but underappreciated determinant of outcome.

5ADAPTIVE IMMUNE EFFECTS SHOW AN AGE‐ASSOCIATED SHIFT IN EOAD MODELS

The inconsistencies observed across depletion studies reveal a patterned shift in immune function during disease progression, suggesting that age is a unifying variable. A broad set of studies has examined how depleting distinct adaptive immune cell subsets influences AD pathology in EOAD mouse models. These investigations span multiple mouse strains introduced in Section 4, including 5xFAD, APPswe/PS1ΔE9, APP/PS1L166P, APPNL‐G‐F, and 3xTg‐AD, and use both genetic and antibody‐mediated approaches to target B cells, T cells, CD8+ T cells, regulatory T cells (Tregs), NK cells, and related pathways.

To examine whether age was associated with differences in adaptive immune function across EOAD models, we performed a targeted literature search using PubMed and Web of Science, combining terms related to AD mouse models and adaptive immune populations, including “Alzheimer's disease,” “mouse,” “5xFAD,” “APP/PS1,” “APPNL‐G‐F,” “3xTg‐AD,” “adaptive immunity,” “T cell,” “CD4,” “CD8,” “regulatory T cell,” “Treg,” “B cell,” “lymphocyte,” “MHC,” “antigen presentation,” “RAG1,” and “RAG2.” Each distinct age‐specific experimental condition was treated as one observation. Where the same study evaluated closely related immune‐deficiency conditions at the same age and reported concordant outcomes, these conditions were grouped as a single age‐specific observation. Thus, studies examining the same manipulation at different ages could contribute more than one observation. Observations were classified according to the inferred functional effect of the immune cell population, rather than the direction of the experimental intervention. Worsening following depletion or genetic deficiency was classified as evidence of a protective immune function, whereas improvement following depletion or deficiency was classified as evidence of a pathogenic immune function. Analysis of 16 independent studies comprising 28 experimental observations reveals a clear age‐dependent shift in the functional roles of adaptive immune components in AD models (Figure 3A). Among 14 observations reported in mice aged 1 to 6 months, eight (≈57%) describe the protective effects of adaptive immune cells,19, 20, 21, 23, 119 while five (≈36%) indicate pathogenic roles16, 118, 120 and one (≈7%) shows no effect.122 In contrast, among 14 observations from mice aged 7 months or older, 10 (≈71%) are pathogenic,15, 17, 23, 118, 120, 121 three (≈21%) are protective,18, 21, 122 and one (≈7%) shows no effect22 (Figure 3B). This analysis is a descriptive synthesis rather than a formal meta‐analysis. Given the substantial heterogeneity across studies in mouse models, immune manipulations, endpoints, and experimental design, individual observations were not weighted by sample size or study quality. Percentages were rounded to the nearest whole number and are presented as descriptive trends rather than pooled estimates of effect.

An important limitation of this comparison is that the included studies differ substantially in the timing and nature of immune manipulation. In particular, knockout mouse models such as RAG2−/− and TCRα−/− mice lack the corresponding lymphocyte populations throughout development. Consequently, phenotypes measured at a given age may reflect developmental compensation or lifelong immune deficiency in addition to the effect of adaptive immunity at that disease stage. Definitive testing of this hypothesis will require temporally controlled immune‐cell depletion or expansion within the same AD model at matched disease stages.

Specifically, at 6 months, a combined RAG2/IL2 deficiency in 5xFAD mice worsened Aβ deposition,20 and early TCRα or MHC‐I deficiency led to cognitive decline.21 In older animals, in contrast, certain interventions targeting defined subsets frequently become protective. Specifically, B‐ or CD8+ T‐cell depletion in 8‐ to 12‐month‐old 5xFAD mice improved cognitive performance and reduced Aβ burden.15, 17 Similarly, RAG2−/−
APP/PS1 mice exhibited increased Aβ pathology at 3 months but reduced pathology by 8 months, directly illustrating a temporal inversion in immune function.23

Some interventions, such as mucosal‐associated invariant T (MAIT) cell depletion120 or gut microbiome perturbation,123 showed protective effects across multiple age groups, suggesting the existence of parallel or co‐interacting mechanisms beyond conventional adaptive immunity. Collectively, these findings demonstrate that adaptive immune activity in EOAD is not static but undergoes stage‐dependent reprogramming.

The contrasting findings from studies of Treg depletion118, 122 further illustrate that age alone may not fully account for the functional effects of adaptive immune populations. In 5xFAD mice, transient conditional depletion of Tregs at 5 to 6 months reduced Aβ pathology and improved cognitive performance, indicating a pathogenic Treg contribution in this context.118 In contrast, anti‐CD25‐mediated Treg depletion in APP/PS1 mice impaired cognitive performance without reducing Aβ pathology, supporting a protective Treg function.122 Because these studies differed in AD model, method, and timing of Treg manipulation and the endpoints assessed, it is difficult to determine which factor, or interaction between factors, accounts for the divergent outcomes. Thus, although age emerges as the clearest overall organizing variable across studies, its effects likely interact with model‐ and intervention‐specific factors in shaping adaptive immune function.

Importantly, this analysis is restricted to predominantly Aβ‐driven EOAD models and does not establish that the same age‐associated shift occurs in tauopathy; whether adaptive immune function undergoes a comparable temporal transition in tau‐driven mouse models remains an open question that requires direct investigation.

6ADDITIONAL BIOLOGICAL MODIFIERS: SEX AND GENETIC CONTEXT

Although age and disease stage provide the clearest framework for interpreting adaptive immunity in AD, they do not fully explain immune heterogeneity across patients and models. Sex and genetic context further shape immune composition, signaling thresholds, and inflammatory tone, requiring biologically stratified interpretation of adaptive immune responses.

6.1Sex differences in adaptive immunity in AD

Globally, of the estimated 32.3 million individuals diagnosed with AD, 20.9 million are women and 11.4 million are men, excluding those in prodromal or preclinical stages.125 This pronounced sex disparity suggests that biological modifiers beyond age alone contribute to disease susceptibility. Sex‐related differences in adaptive immunity are a compelling mechanistic candidate underlying this imbalance. Compared with men, women generally mount stronger adaptive immune responses, characterized by higher CD4+ T‐cell counts and more robust B‐cell‐mediated antibody production. These differences are driven in part by inflammation‐related X chromosome‐linked genes that escape X‐inactivation, thereby amplifying immune signaling in females.126 Such baseline immune dimorphism creates a distinct immunological environment in women that may shape the initiation and progression of AD‐relevant neuroinflammatory processes.

The menopausal transition represents a major inflection point in this immune landscape. Because B cells and CD4+ T cells express estrogen receptors, adaptive lymphocytes are directly responsive to circulating estrogen levels.126, 127, 128 Declining estrogen can therefore disrupt estrogen receptor‐mediated immune regulation, promoting a more pro‐inflammatory state marked by altered T‐cell ratios, reduced B‐cell numbers, and increased systemic inflammatory signaling.129, 130 Such remodeling is associated with increased Aβ accumulation and greater vulnerability to AD progression.131, 132, 133, 134

Menopausal hormone therapy (MHT) may modify these trajectories,135 but its immunological effects are not uniform136, 137, 138, 139, 140 (Table S1). Estrogen signaling regulates thymic T‐cell development, T‐cell polarization, activation thresholds, B‐cell selection, and tolerance checkpoints,136, 141, 142, 143 while other hormones such as progesterone and progestogens further shape adaptive immune responses and T‐cell–microglia interactions.144, 145 Consistent with this mechanistic framework, clinical and experimental studies demonstrate that MHT measurably reprograms T‐ and B‐cell compartments, with effects that differ according to hormone formulation and route of administration135, 146, 147, 148 (Table S1).

These context‐dependent immune effects may help explain divergent associations between MHT and AD risk. While large randomized trials in older postmenopausal women have reported an increased incidence of dementia,149 observational studies of MHT initiated in midlife generally report either neutral or protective associations.150 Recent integrative reviews further emphasize that the effect of MHT on AD risk depends on initiation near the menopausal transition and APOE ε4 genotype.150 These differences are consistent with the immunomodulatory effects of estradiol on T‐cell polarization and B‐cell tolerance described earlier.141, 142, 144, 151 Accordingly, regimens that restore estradiol signaling without exacerbating systemic inflammatory pathways or promoting autoreactive B‐cell selection may help preserve a more youthful immune phenotype. Such coordinated immune effects could attenuate chronic low‐grade inflammation and modulate microglia–T‐cell crosstalk, thereby slowing Aβ pathology.136 In contrast, late initiation in an already immunosenescent and pro‐inflammatory immune environment may reinforce maladaptive humoral and innate activation and thereby fail to confer, or even worsen, AD risk.152 Taken together, these observations support the view that MHT effects on AD risk are determined by the interaction between therapy timing and the underlying immune state rather than by a uniform treatment effect.

6.2Adaptive immunity in DS‐associated AD (DSAD)

While sex differences illustrate how physiological factors shape adaptive immune responses with age, genetic conditions associated with EOAD pathology provide an additional framework for examining immune dysregulation in AD. DS is the most prominent and prevalent example, as individuals with DS develop early amyloid pathology and exhibit chronic immune activation, offering a powerful framework for examining how adaptive immunity contributes to AD pathogenesis in this syndrome. Genetically defined EOAD contexts help distinguish adaptive immune responses driven primarily by amyloid pathology from those amplified by broader genetic perturbation of immunity.

6.2.1Genetic interferonopathy drives neuroimmune vulnerability in DS

Individuals with DS exhibit a genetically determined predisposition to AD driven primarily by triplication of human chromosome 21 (Hsa21), which results in ∼1.3‐fold increased APP expression and profound immune dysregulation.153 Accordingly, Aβ deposition and tau pathology typically emerge in the fourth decade of life, followed by progression to nearly universal dementia by the sixth or seventh decade. Under the revised Alzheimer's Association criteria, individuals with genetically determined AD, including DSAD, are classified as Stage 0 while biomarker‐negative and clinically asymptomatic, reflecting the presence of the underlying disease‐associated genotype from birth.154 Beyond APP, the triplicated genome includes additional AD‐related genes such as dual‐specificity tyrosine‐phosphorylation‐regulated kinase 1A (DYRK1A), whose overexpression disrupts endosomal trafficking, promotes aberrant APP processing, enhances tau phosphorylation, and contributes to synaptic dysfunction.155

DS provides a uniquely informative context for understanding how genetically driven amyloid burden intersects with immune dysregulation to accelerate AD pathophysiology.156, 157 A central and parallel feature of trisomy 21 is constitutive type I IFN (IFN‐I) hypersensitivity. Triplication of IFN‐α and β receptor subunits 1 and 2 (IFNAR1 and IFNAR2) increases receptor expression by ∼50%, causing physiological levels of IFN‐α and β to trigger exaggerated Janus kinase‐signal transducer and activator of transcription (JAK‐STAT) signaling and chronic induction of IFN‐stimulated genes. This response is further amplified by the triplication of Hsa21‐encoded antiviral IFN‐stimulated genes, including MX dynamin‐like GTPase 1 and 2 (MX1 and MX2) and IFN‐induced transmembrane protein 1 and 3 (IFITM1 and IFITM3), which enhance downstream transcriptional activation. These gene–dosage effects create a lifelong interferonopathy detectable from infancy and characterized by heightened basal inflammation and premature immune aging.158

This chronic IFN‐I signaling, in turn, reshapes the adaptive immune system in ways that are implicated in AD pathogenesis. IFN‐I accelerates thymic involution, reduces naïve T‐cell output, and drives early expansion of effector and TEMRA T cells, hallmarks of advanced immunological aging. These highly differentiated T‐cell populations exhibit increased cytotoxicity and elevated IFN‐γ secretion, thereby lowering the activation threshold of microglia and promoting pro‐inflammatory microglial states. Similarly, lifelong exposure to IFN‐I disrupts B‐cell maturation and class switching, reduces naïve B‐cell pools, and promotes exhausted or autoreactive B‐cell phenotypes, producing a humoral compartment that is hyperactivated yet functionally inefficient, a pattern that mirrors B‐cell dysregulation observed in sporadic AD but emerges decades earlier in DSAD.153

6.2.2Neuroimmune amplification of AD pathology in DS

Within the CNS, chronic IFN‐I signaling drives microglia toward a maladaptive activation state. Although acute IFN‐I exposure can transiently enhance Aβ clearance,159 sustained signaling progressively disrupts lysosomal pathways, reduces phagocytic efficiency, and increases pro‐inflammatory cytokine release, thereby promoting both Aβ accumulation and tau phosphorylation. As a result, IFN‐I hypersensitivity establishes a feedforward loop in which peripheral adaptive immune aging exacerbates microglial dysfunction,160 while microglial stress further promotes the recruitment and activation of cytotoxic T‐cells at the brain borders.161 These alterations produce systemic inflammation, impaired immune regulation, and accelerated immunosenescence that closely mirror and markedly intensify the immune perturbations observed in sporadic AD, thereby accelerating AD neurodegeneration in DS. These converging neuropathological and immunological features position DS as a genetically defined framework for investigating early AD mechanisms.156, 162

6.2.3APP duplication as a minimal amyloid‐driven immune context

In contrast to DS, duplication of the APP gene (located on chromosome Hsa21) represents a genetically defined form of EOAD characterized by increased APP dosage in the absence of triplication of immune‐related genes.163, 164 Individuals with APP duplication develop early and robust Aβ pathology, similar to that observed in DS, but without the constitutive IFN signaling and systemic immune dysregulation associated with trisomy 21.165 Accordingly, APP duplication may reflect a “minimal” model of amyloid‐induced immune engagement, whereas DS represents a “maximal” neuroimmune context in which amyloid pathology and intrinsic immune dysregulation converge.163 Comparing these conditions may therefore help clarify the extent to which adaptive immune responses in AD are triggered by Aβ itself or shaped by underlying immune‐genetic background.

6.3Therapeutic implications and clinical translation

The oligomerization of Aβ monomers and their subsequent aggregation into neuritic plaques occur silently during a decades‐long presymptomatic phase, followed by inflammation and tau pathology that drive neurodegeneration and clinical symptoms. This temporal trajectory suggests that anti‐Aβ therapies are likely to be the most effective when initiated early in the disease course, before irreversible neuronal damage occurs.52, 166 As immune‐based therapies have progressed from conceptual strategies to clinical implementation, it has become evident that the manner in which adaptive immunity is engaged critically determines both therapeutic efficacy and safety. Interestingly, population‐level evidence suggests that immune interventions not specifically directed against AD pathology may also influence dementia risk. In a natural experiment exploiting age‐based eligibility for herpes zoster vaccination, receipt of a vaccine was associated with a significant reduction in the probability of a new dementia diagnosis over 7 years.167

Early attempts to harness adaptive immunity demonstrated that antibody‐mediated clearance of Aβ is feasible. However, these studies also exposed the risks associated with the unintended activation of pro‐inflammatory T‐cell pathways.14 These early safety signals have guided the development of next‐generation immunotherapies that aim to elicit robust and durable humoral responses with minimal cellular autoreactivity. In parallel, studies isolating memory B cells reactive to Aβ from patients with AD provide functional evidence that an adaptive immune, B‐cell‐dependent response against amyloid pathology can be effectively generated in humans. These observations complement reports of naturally occurring anti‐Aβ antibodies and further strengthen the biological rationale for antibody‐based therapeutic strategies.166, 168 Within this evolving therapeutic landscape, two principal immunological strategies have emerged: active vaccination, which seeks to induce sustained cellular and endogenous polyclonal humoral anti‐Aβ and/or anti‐tau responses, and passive immunization, which delivers highly specific monoclonal antibodies to accelerate amyloid removal with controlled target engagement. Understanding how these complementary approaches mobilize adaptive immunity provides essential context for evaluating their clinical outcomes and for interpreting the variability in efficacy and safety observed across disease stages and patient populations.

6.4Active vaccination: humoral engagement versus T‐cell liability

One of the earliest landmark efforts in AD immunotherapy was the AN1792 trial, which evaluated a full‐length Aβ42 active first‐generation vaccine formulated with the QS‐21 adjuvant, developed by Elan Pharmaceuticals. Although AN1792 generated functional anti‐Aβ antibodies that were associated with plaque clearance in responders, the phase 2a trial with this vaccine was halted prematurely due to meningoencephalitis in ∼6% of participants14 (Table 4). Subsequent analyses demonstrated that these adverse events were driven by a pro‐inflammatory, Th1‐skewed T‐cell response, particularly in participants who received a formulation containing polysorbate 80.13 This experience exemplified the need for vaccine designs that elicit robust B‐cell‐mediated humoral immunity while avoiding autoreactive T‐cell activation. Although AN1792 generated functional anti‐Aβ antibodies and evidence of amyloid clearance, long‐term neuropathological follow‐up demonstrated that substantial, and in some cases nearly complete, plaque removal did not prevent progression to severe dementia or ongoing neurodegeneration.169 This dissociation between amyloid removal and clinical progression supports the possibility that Aβ‐directed intervention may have limited efficacy once downstream neurodegenerative processes are established.

In response, second‐generation active vaccines have been engineered and are currently in clinical development. UB‐311, a synthetic peptide vaccine developed by United Biomedical, is engineered to induce a predominantly B‐cell‐driven, Th2‐skewed immune response. In a phase 2a trial in mild AD, it elicited antibody responses in >90% of participants and demonstrated a favorable safety profile12 (Table 4). ACI‐24.060, a liposome‐based vaccine developed by AC Immune that presents the Aβ15 epitope in a β‐sheet conformation, is similarly designed to promote humoral immunity while minimizing T‐cell‐mediated inflammation.11 Notably, this program includes participants with DS, recognizing their unique vulnerability to AD. Interim data from the ongoing ABATE trial (a phase 1b/2 study evaluating ACI‐24.060 in AD and DS populations) indicate early induction of anti‐Aβ antibodies, although quantitative titers, durability, and clinical impact remain under evaluation (Table 4). In parallel, additional peptide‐based vaccine platforms have sought to refine Aβ targeting and minimize the risk of autoreactive T‐cell activation. CAD106 (Novartis) and ACC‐001 (Janssen) both employed short N‐terminal Aβ epitopes conjugated to carrier proteins and achieved robust anti‐Aβ antibody responses with acceptable tolerability, though phase 2 development was discontinued in the absence of clear clinical benefit. More recently, ABvac40, a vaccine targeting the C‐terminus of Aβ40, completed a phase 2 trial in early AD, demonstrating good tolerability, durable antibody titers, and exploratory signs of benefit on cognition and brain atrophy, particularly in relation to vascular amyloid burden.170

In addition to Aβ‐directed strategies, tau‐targeting vaccines are emerging as a complementary approach that directly engages adaptive immunity against the protein species most tightly linked to neurodegeneration. AADvac1, an active vaccine directed against a pathological microtubule‐binding region of tau, demonstrated good safety and strong antibody responses in the ADAMANT phase 2 clinical trial, with post hoc analyses suggesting potential benefit in biomarker‐defined subgroups characterized by elevated plasma p‐tau217.171 Importantly, the evaluation of the AADvac1 vaccine includes a combination with anti‐Aβ monoclonal antibodies. Similarly, the liposomal vaccine ACI‐35.030 and its conjugated analog JACI‐35.054, designed to present phosphorylated tau (pTau) epitopes in an immunogenic configuration, have elicited strong pTau‐specific humoral responses with acceptable tolerability in early‐phase trials.172

Collectively, these candidates demonstrate the field's progression from full‐length Aβ vaccination toward epitope‐focused, B‐cell‐driven approaches with increased efforts toward combined targeting of tau pathology. This progression reflects a broader effort to maximize immunogenicity while minimizing T‐cell‐mediated neuroinflammation and to extend adaptive immune targeting beyond amyloid to downstream drivers of neurodegeneration.

6.5Passive immunization: early‐stage benefit and amyloid‐related imaging abnormality (ARIA)‐defined limits

Passive Aβ‐targeting immunotherapies have reshaped the therapeutic landscape of AD. Aducanumab (the EMERGE/ENGAGE trials),173 lecanemab (the CLARITY‐AD trial),174 and donanemab (the TRAILBLAZER‐ALZ 2 trial)175 have each demonstrated robust Aβ‐plaque clearance and modest, but statistically significant, slowing of cognitive and functional decline, with the strongest effects observed in patients at earlier disease stages.

Lecanemab received full US Food and Drug Administration (FDA) approval in 2023 after demonstrating clinical benefit in early symptomatic AD. Following 18 months of treatment, cognitive decline was reduced by 27%, as measured by the Clinical Dementia Rating–Sum of Boxes, with consistent benefits across additional cognitive and functional scales.166 Donanemab received full FDA approval in July 2024 for patients with mild cognitive impairment or mild AD with confirmed Aβ pathology, based on phase 3 data showing slowed cognitive and functional decline, particularly among individuals with intermediate tau pathology.166 Both lecanemab and donanemab are associated with significant adverse effects, most notably ARIA, and are therefore recommended primarily for carefully selected early‐stage patients following genetic and biomarker screening.166 ARIA are thought to arise partly from antibody‐mediated mobilization of Aβ in the presence of vascular amyloid/CAA, which can promote vascular inflammation, BBB disruption, edema (ARIA‐E), and hemorrhagic lesions (ARIA‐H).176 Aducanumab, previously granted accelerated approval based primarily on its Aβ‐lowering effect, was fully discontinued in 2024, with Biogen halting both development and commercialization after years of controversy and limited clinical uptake.166 Lecanemab and donanemab now represent the standard Aβ immunotherapies with full FDA approval, whereas aducanumab is no longer available.177, 178, 179 Newer delivery strategies aim to improve brain exposure while limiting vascular toxicity. Trontinemab, an anti‐Aβ antibody fused to a transferrin receptor 1‐targeting Brainshuttle, has shown rapid amyloid plaque clearance with a low observed incidence of ARIA in early‐phase studies, although larger trials are required to establish its long‐term safety and clinical efficacy.180

Beyond these agents, a new generation of high‐affinity anti‐Aβ antibodies is advancing through late‐stage development. Among these, remternetug is entering phase 3 trials and is designed to achieve more rapid plaque clearance, along with more convenient subcutaneous administration. However, it remains uncertain whether these pharmacodynamic advances will translate into greater clinical benefit or meaningfully alter ARIA risk.181

6.6Antibody‐ and fragment crystallizable (Fc)‐mediated mechanisms beyond canonical anti‐Aβ monoclonal antibodies

Intravenous Ig (IVIG) is a therapeutic preparation consisting of pooled IgG antibodies collected from the plasma of thousands of healthy blood donors,182 encompassing a broad repertoire that includes naturally occurring antibodies against Aβ and other self‐antigens. In AD, IVIG has been explored for its potential to neutralize toxic Aβ species, modulate microglial activation, and restore immune homeostasis. The majority of Aβ‐binding natural antibodies within IVIG are conformation‐selective, preferentially recognizing oligomeric and fibrillar forms of Aβ (see review by Relkin183). A phase 3 clinical trial of IVIG administration to individuals with mild to moderate LOAD did not demonstrate a cognitive benefit.184 In contrast, preclinical studies further indicate that IVIG effects are variable and depend on treatment timing and disease context. For example, in 19‐month‐old APP/PS1 mice, peripheral IVIG administration increased BBB permeability and antibody infiltration into the brain parenchyma, with colocalization to Aβ plaques, and enhanced microglial clearance of Aβ ex vivo.185 In contrast, prolonged IVIG treatment initiated at 4 months of age did not reduce Aβ burden despite increased infiltration of CD45+ immune cells.186 In young 3xTg‐AD mice, early IVIG treatment corrected the elevated CD4/CD8 T‐cell ratio and reduced the oligomeric Aβ levels.187 In the same model, IVIG treatment was also associated with reduced tau pathology.188 Intracranial IVIG reduced brain Aβ levels and was associated with decreased inflammatory signaling and increased neurogenesis across AD mouse models.189, 190

While Igs have been implicated in modulating pathology in EOAD mouse models, direct causal evidence remains limited, as no studies have investigated AD‐related outcomes in Ig‐deficient EOAD mouse models. Consistent with the lack of clinical efficacy in established LOAD, preclinical findings suggest complex, model‐ and timing‐dependent effects that warrant further investigation into its mechanisms and potential efficacy at earlier disease stages.

Given that the biological activity of IVIG and other Ig‐based interventions is largely mediated through Fc‐Fcγ receptor (FcγR) interactions,191 understanding FcγR expression and signaling within the CNS is essential for interpreting their effects in AD. Importantly, findings from human‐derived IVIG studies in mouse models should be interpreted with caution due to species‐specific differences in Ig‐FcγR binding affinity and downstream signaling.192 Further, the ability of IVIG to engage activating and inhibitory FcγRs determines whether downstream responses are anti‐inflammatory and neuroprotective or, conversely, pro‐inflammatory and neurotoxic.193 Thus, while IVIG studies highlight the therapeutic potential of antibody‐mediated mechanisms, they also underscore the need to consider the local FcγR landscape within the brain as a key modulator of Ig function and outcome in AD.

Several FcγR‐related mechanisms have been proposed in AD pathogenesis, reflecting the diverse ways in which Ig‐FcγR interactions can influence neuronal survival and neuroinflammation (see review by Fuller et al.193). These mechanisms suggest that Ig‐FcγR signaling can promote either neurodegeneration or immune‐mediated clearance depending on context. Importantly, combined APOE and FcγR developmental deficiency in mice confers protection against neuropathological and cognitive alterations compared with APOE‐deficient mice alone.194 These reports underscore the need for more systematic investigation of Ig involvement in AD etiology. Accordingly, the use of Ig‐deficient mouse models may help clarify the precise contribution of Ig to AD pathogenesis.

6.7DS as a stratified translational setting

Historically, individuals with DS have been systematically excluded from pivotal AD trials, such as those evaluating anti‐Aβ monoclonal antibodies, including lecanemab and donanemab, largely because of eligibility criteria that indirectly resulted in disqualification from the trials. Specifically, many studies excluded participants with intellectual disabilities, imposed age ranges that were misaligned with the earlier onset of AD in individuals with DS, and relied on cognitive outcome measures that have not been validated for this population (see review by Barroeta et al.156). In recent years, however, the field has begun to address this gap by developing disease‐modifying and symptomatic clinical trials specifically tailored to the distinctive biology of DSAD.

The Trial‐Ready Cohort for DS (TRC‐DS) (NCT04165109), initiated under the Alzheimer's Clinical Trials Consortium (ACTC)‐DS network, has established the biomarker infrastructure and recruitment platform that enables intervention studies in adults with DS aged 25 to 55. Building on this preparatory framework, several targeted interventional programs are now under way. The ABATE trial (NCT05462106) began enrollment in 2024 to evaluate ACI‐24.060, an active anti‐Aβ vaccine in asymptomatic or prodromal individuals with DS (ages 35 to 50), and reported favorable interim safety data by late 2024. The HERO study (NCT06673069), launched in 2024, is a phase 1b single‐ascending‐dose trial of ION269, an antisense oligonucleotide that suppresses APP‐derived Aβ production in amyloid‐positive adults with DS (35 to 55 years). The forthcoming ALADDIN trial (NCT06911944), which opened recruitment in 2025, will evaluate donanemab in individuals with DS (35 to 50 years), with particular emphasis on safety and on monitoring ARIA through rigorous magnetic resonance imaging protocols. Complementing these disease‐modifying efforts, parallel strategies are targeting symptomatic and network‐level dysfunction in DSAD. The LESS‐AD study (NCT07234695), coordinated by Hospital de Sant Pau in Spain, aims to evaluate whether levetiracetam, a drug typically used to prevent epilepsy, can delay neurodegeneration and support seizure prevention in individuals with DSAD. It is currently recruiting participants as of 2025. Collectively, these emerging clinical trials represent a pivotal step in the therapeutic development pipeline for DSAD. By integrating biomarker‐driven designs with immune‐targeted interventions within a genetically defined population, these studies offer a powerful translational framework to dissect how adaptive immune alterations influence amyloid processing, neuroinflammation, and disease progression.

6.8Toward stage‐ and context‐specific immunomodulation in AD

The collective evidence reviewed here indicates that adaptive immunity in AD cannot be effectively targeted using uniform therapeutic strategies. Across human studies, genetic analyses, experimental models, and clinical trials, adaptive immune responses are not fixed in function but dynamically evolve across disease progression. Age and disease stage consistently emerge as the most reliable determinants of whether adaptive immune activity is protective or pathogenic. In contrast, sex, genetic background, and baseline immune state further modulate these effects. These observations argue for a shift from generalized immune targeting toward a precision immunomodulation framework in which therapeutic interventions are aligned with the immunological and pathological state of the individual. Immune checkpoint modulation provides a particularly illustrative example of this context dependence. Systemic programmed cell death protein 1 (PD‐1) blockade induced an IFN‐γ‐dependent immune response, promoted recruitment of peripheral monocyte‐derived macrophages to the brain, reduced Aβ pathology, and improved cognitive performance in AD mouse models.195 However, these findings were not reproduced in a subsequent study, which observed peripheral immune activation following anti‐PD‐1 treatment but no detectable monocyte‐derived macrophage infiltration into the brain or reduction in cerebral Aβ pathology across several amyloid mouse models.196

The first principle of such an approach is temporal specificity. Evidence from EOAD mouse models demonstrates that early in the disease course, adaptive immune components often support protective functions, including immune surveillance, modulation of microglial activity, and facilitation of Aβ clearance. In contrast, at later stages, the same immune compartments can become maladaptive, contributing to chronic inflammation, impaired clearance mechanisms, and neurotoxicity. Clinical data are consistent with this pattern, as anti‐Aβ monoclonal antibodies show the greatest efficacy when administered in early symptomatic or prodromal stages, whereas interventions applied later yield limited benefit. These findings suggest that the timing of immune engagement is not merely a practical consideration but a central determinant of therapeutic outcome.

The second principle is cell type specificity. Adaptive immunity in AD is not a single axis but a composite of functionally distinct cell populations with divergent roles. Tregs, for example, may restrain excessive inflammation and support homeostasis in early disease, whereas cytotoxic or other pathogenic CD8+ T cells and certain B‐cell subsets may contribute to pathology at later stages. This concept has begun to translate into clinical research. Low‐dose IL‐2, which preferentially expands Tregs, was shown to be safe and to increase circulating Treg numbers in a phase 1 study of patients with AD.197 More recently, a randomized phase 2a trial demonstrated increased Treg abundance and suppressive function together with changes in inflammatory and AD‐related CSF biomarkers, supporting the feasibility of therapeutically restoring Treg activity in AD.198 Similarly, the evolution of vaccine design from full‐length Aβ immunization to epitope‐focused, B‐cell‐driven strategies reflects an increasing recognition that selective engagement of humoral immunity, while minimizing pro‐inflammatory T‐cell activation, is critical for safety and efficacy. However, a detailed, stage‐resolved map linking specific T‐ and B‐cell subsets to protective versus pathogenic functions remains lacking. Defining these relationships represents a major barrier to rational therapeutic design.

The third principle is host stratification. Adaptive immune responses in AD are shaped by systemic biological context. Sex‐related immune dimorphism, particularly the immunological consequences of menopause, alters T‐cell polarization, B‐cell function, and inflammatory tone. Genetic factors, including APOE genotype and immune‐related risk loci, further influence antigen presentation, lymphocyte activation, and microglial interactions. In parallel, conditions such as DS illustrate how chronic immune activation and IFN signaling can profoundly reshape adaptive immunity and accelerate AD pathology. These factors indicate that patients do not share a uniform immune landscape and that effective immunomodulation will require stratification based on biological variables that influence immune function.

7OPEN QUESTIONS AND FUTURE DIRECTIONS

Despite rapid advances, our understanding of how adaptive immunity shapes AD pathogenesis remains incomplete. Future research must determine when and through which mechanisms adaptive immune responses shift from protective or regulatory roles toward pathogenic activities and define the pathophysiological conditions under which these transitions occur, including the cellular and temporal dynamics of B‐ and T‐cell activity across disease progression.

First, does biological age itself causally alter the function of adaptive immune cells during AD progression? The age‐associated pattern identified across EOAD models suggests that adaptive immune populations may exert protective effects earlier in disease and increasingly pathogenic effects at later stages. However, many existing studies rely on constitutive immune deficiencies, such as RAG‐ or TCR‐deficient mice, in which lymphocyte populations are absent throughout development. Such models cannot distinguish the effects of immune aging from developmental compensation or lifelong immune deficiency. This hypothesis therefore requires direct testing using temporally controlled depletion or expansion of defined immune‐cell populations within the same AD model at matched early and late disease stages. Complementary heterochronic lymphocyte‐transfer experiments, in which lymphocytes from young and aged donors are transferred into age‐matched or age‐mismatched recipients, could distinguish cell‐intrinsic effects of immune aging from those imposed by the aged systemic or CNS environment. Parabiosis approaches could similarly determine the extent to which circulating age‐associated factors reprogram adaptive immune function. Importantly, the present age‐associated analysis is restricted predominantly to Aβ‐driven EOAD models and does not establish that the same temporal shift occurs in tauopathy; comparable age‐resolved experiments in tau‐driven models will therefore be essential.

Second, which antigen‐specific T‐ and B‐cell populations drive protective versus pathogenic responses, and where are these responses initiated? It remains unclear which CD8+ T‐cell populations mediate neurotoxicity versus immune surveillance, which B‐cell subsets support protective antibody responses rather than autoreactivity, and whether these functions differ between amyloid‐ and tau‐dominated disease states. Likewise, the antigens driving clonal T‐ and B‐cell expansion remain incompletely defined. Longitudinal paired TCR‐ and BCR‐repertoire sequencing across blood, CSF, meninges, cervical lymph nodes, and brain could determine whether expanded clones are shared across anatomical compartments and how their abundance and phenotype change with disease progression. Combining repertoire analysis with single‐cell transcriptomics, spatial profiling, and unbiased antigen‐discovery approaches will be required to identify the cognate antigens driving these clones and determine whether they preferentially recognize Aβ, tau, microbial antigens, or other CNS‐derived targets. Such studies could also establish whether adaptive immune priming occurs primarily in cervical lymph nodes, meningeal immune niches, or other peripheral compartments and why antigen exposure promotes tolerance in some contexts but sustained inflammatory responses in others.

Third, can stage‐specific adaptive immune states be translated into biomarkers that guide therapeutic intervention? Adaptive immune responses in AD are shaped not only by disease stage but also by sex, genetic background, and baseline immune state. Sex‐linked immune differences, X‐chromosome escapee genes, and risk alleles such as APOE and HLA‐DRB1 may collectively establish distinct immunological set points that influence how adaptive immunity responds to emerging pathology. Genetically defined contexts such as DS may provide an additional framework for dissecting these interactions, particularly by comparing it with APP duplication to distinguish amyloid‐driven immune activation from broader immune‐genetic dysregulation. Longitudinal human studies should therefore integrate peripheral and CSF immune profiling with Aβ and tau biomarkers, age, sex, genotype, and clinical disease stage to identify immune signatures associated with protective versus pathogenic states. Ultimately, immune‐stratified clinical trials will be required to determine whether selecting patients by immunological state, rather than diagnosis alone, improves the efficacy and safety of immune‐directed therapies.

8CONCLUSION

The body of evidence presented herein demonstrates that adaptive immunity is a central and multifaceted contributor to AD pathophysiology. Human studies show that T‐ and B‐cell responses engage AD‐relevant brain compartments, with T cells more closely associated with tau pathology and B cells/antibodies linked primarily to Aβ burden. Complementing these observations, GWASs have identified genetic loci linked to adaptive immune processes, reinforcing the mechanistic relevance of antigen presentation, lymphocyte regulation, and Ig‐mediated pathways. Experimental evidence further supports this framework as findings from EOAD mouse models illustrate that adaptive immune activity is highly context‐ and age‐dependent.

Together, these insights suggest that adaptive immunity is neither uniformly detrimental nor uniformly protective in AD but instead operates along a dynamic spectrum shaped by intrinsic and extrinsic factors. This spectrum is further modulated by host‐specific biological contexts. Additional modifiers, including sex‐related immune dimorphism, genetic risk architecture, and IFN‐driven immune remodeling observed in DS, illustrate how host‐specific factors shape adaptive immune behavior across the AD spectrum. Accordingly, therapeutic strategies aimed at modulating adaptive immunity will require careful tailoring, particularly with respect to the stage of the disease at which such interventions are introduced.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest. Author disclosures are available in the Supporting Information.

Supporting information

REFERENCES

1Liu W , Deng W , Gong X , Ou J , Yu S , Chen S . Global burden of Alzheimer's disease and other dementias in adults aged 65 years and over, and health inequality related to SDI, 1990‐2021: analysis of data from GBD 2021 . BMC Public Health . 2025 ;25 (1 ):1256 . doi:10.1186/s12889-025-22378-z PMC11969849 40181335

2Xie J , Van Hoecke L , Vandenbroucke RE . The impact of systemic inflammation on Alzheimer's disease pathology . Front Immunol . 2021 ;12 :796867. doi:10.3389/fimmu.2021.796867 PMC8770958 35069578

3Kinney JW , Bemiller SM , Murtishaw AS , Leisgang AM , Salazar AM , Lamb BT . Inflammation as a central mechanism in Alzheimer's disease . Alzheimers Dement . 2018 ;4 :575 ‐590 . doi:10.1016/j.trci.2018.06.014
PMC6214864 30406177

4Agnello L , Gambino CM , Ciaccio AM , et al. From amyloid to synaptic dysfunction: biomarker‐driven insights into Alzheimer's disease . Curr Issues Mol Biol .2025 ;47 (8 ): 580 . doi:10.3390/cimb47080580
PMC12384784 40864734

5Hampel H , Hardy J , Blennow K , et al. The amyloid‐β pathway in Alzheimer's disease . Mol Psychiatry . 2021 ;26 (10 ). 5481 ‐5503 . doi:10.1038/s41380-021-01249-0
PMC8758495 34456336

6Gamblin TC , Chen F , Zambrano A , et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease . Proc Natl Acad Sci U S A . 2003 ;100 (17 ):10032 ‐10037 . doi:10.1073/pnas.1630428100
PMC187753 12888622

7Da Mesquita S , Fu Z , Kipnis J . The meningeal lymphatic system: a new player in neurophysiology . Neuron . 2018 ;100 (2 ):375 ‐388 . doi:10.1016/j.neuron.2018.09.022
PMC6268162 30359603

8Iliff JJ , Wang M , Liao Y , et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β . Sci Transl Med . 2012 ;4 (147 ):147ra111. doi:10.1126/scitranslmed.3003748
PMC3551275 22896675

9Li Y , Laws SM , Miles LA , et al. Genomics of Alzheimer's disease implicates the innate and adaptive immune systems . Cell Mol Life Sci . 2021 ;78 (23 ):7397 ‐7426 . doi:10.1007/s00018-021-03986-5
PMC11073066 34708251

10Wightman DP , Jansen IE , Savage JE , et al. A genome‐wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease . Nat Genet . 2021 ;53 (9 ):1276 ‐1282 . doi:10.1038/s41588-021-00921-z
PMC10243600 34493870

11Maggos C . AC Immune's ACI‐24.060 anti‐amyloid beta vaccine for Alzheimer's shows positive initial interim safety and immunogenicity in phase 1b/2 ABATE trial . AC Immune.

12Yu HJ , Dickson SP , Wang P‐N , et al. Safety, tolerability, immunogenicity, and efficacy of UB‐311 in participants with mild Alzheimer's disease: a randomised, double‐blind, placebo‐controlled, phase 2a study . EBioMedicine . 2023 ;94 :104665. doi:10.1016/j.ebiom.2023.104665
PMC10338203 37392597

13Pride M , Seubert P , Grundman M , Hagen M , Eldridge J , Black RS . Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792‐associated meningoencephalitis . Neurodegener Dis . 2008 ;5 (3‐4 ):194 ‐196 . doi:10.1159/000113700
18322388

14Schenk D . Amyloid‐beta immunotherapy for Alzheimer's disease: the end of the beginning . Nat Rev Neurosci . 2002 ;3 (10 ):824 ‐828 . doi:10.1038/nrn938
12360327

15Kim Ki , Wang X , Ragonnaud E , et al. Therapeutic B‐cell depletion reverses progression of Alzheimer's disease . Nat Commun . 2021 ;12 (1 ):2185 . doi:10.1038/s41467-021-22479-4
PMC8042032 33846335

16Van Hoecke L , Castelein J , Xie J , et al. An immunological puzzle: the adaptive immune system fuels Alzheimer's disease pathology . Brain Behav Immun . 2024 ;117 :122 ‐134 . doi:10.1016/j.bbi.2023.12.026
38142916

17Wang X , Campbell B , Bodogai M , et al. CD8+ T cells exacerbate AD‐like symptoms in mouse model of amyloidosis . Brain Behav Immun . 2024 ;122 :444 ‐455 . doi:10.1016/j.bbi.2024.08.045
PMC11409913 39191349

18Faridar A , Vasquez M , Thome AD , et al. Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's disease . Acta Neuropathol Commun . 2022 ;10 (1 ):144 . doi:10.1186/s40478-022-01447-z
PMC9524037 36180898

19Feng W , Zhang Y , Ding S , et al. B lymphocytes ameliorate Alzheimer's disease‐like neuropathology via interleukin‐35 . Brain Behav Immun . 2023 ;108 :16 ‐31 . doi:10.1016/j.bbi.2022.11.012
36427805

20Marsh SE , Abud EM , Lakatos A , et al. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function . Proc Natl Acad Sci U S A . 2016 ;113 (9 ):E1316 ‐E1325 . doi:10.1073/pnas.1525466113
PMC4780638 26884167

21Su W , Saravia J , Risch I , et al. CXCR6 orchestrates brain CD8+ T cell residency and limits mouse Alzheimer's disease pathology . Nat Immunol . 2023 ;24 (10 ):1735 ‐1747 . doi:10.1038/s41590-023-01604-z
PMC11102766 37679549

22Unger MS , Li E , Scharnagl L , et al. CD8+ T‐cells infiltrate Alzheimer's disease brains and regulate neuronal‐ and synapse‐related gene expression in APP‐PS1 transgenic mice . Brain Behav Immun . 2020 ;89 :67 ‐86 . doi:10.1016/j.bbi.2020.05.070
32479993

23Späni C , Suter T , Derungs R , et al. Reduced β‐amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells . Acta Neuropathol Commun . 2015 ;3 :71 . doi:10.1186/s40478-015-0251-x
PMC4642668 26558367

24Cancro MP . Age‐Associated B Cells . Annu Rev Immunol . 2020 ;38 :315 ‐340 . doi:10.1146/annurev-immunol-092419-031130
31986068

25Bodogai M , O'Connell J , Kim K , et al. Commensal bacteria contribute to insulin resistance in aging by activating innate B1a cells . Sci Transl Med . 2018 ;10 (467 ): eaat4271. doi:10.1126/scitranslmed.aat4271
PMC6445267 30429354

26Bodogai M , Park B , Braikia F‐Z , et al. A distinct population of CD8+ T cells expressing CD39 and CD73 accumulates with age and supports cancer progression . Nat Aging . 2025 ;5 (10 ):2055 ‐2069 . doi:10.1038/s43587-025-00966-3
40999030

27Delgado‐Pulido S , Yousefzadeh MJ , Mittelbrunn M . Aging reshapes the adaptive immune system from healer to saboteur . Nat Aging . 2025 ;5 (8 ):1393 ‐1403 . doi:10.1038/s43587-025-00906-1
40813808

28Elyahu Y , Hekselman I , Eizenberg‐Magar I , et al. Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes . Sci Adv . 2019 ;5 (8 ):eaaw8330. doi:10.1126/sciadv.aaw8330
PMC6703865 31457092

29Mogilenko DA , Shpynov O , Andhey PS , et al. Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging . Immunity . 2021 ;54 (1 ):99 ‐115 . doi:10.1016/j.immuni.2020.11.005
33271118

30Terekhova M , Swain A , Bohacova P , et al. Single‐cell atlas of healthy human blood unveils age‐related loss of NKG2C . Immunity . 2023 ;56 (12 ):2836 ‐2854 . doi:10.1016/j.immuni.2023.10.013
37963457

31Lau SF , Fu AKY , Ip NY . Cytokine signaling convergence regulates the microglial state transition in Alzheimer's disease . Cell Mol Life Sci . 2021 ;78 (10 ):4703 ‐4712 . doi:10.1007/s00018-021-03810-0
PMC8195901 33847763

32Sulzer D , Alcalay RN , Garretti F , et al. T cells from patients with Parkinson's disease recognize α‐synuclein peptides . Nature . 2017 ;546 (7660 ):656 ‐661 . doi:10.1038/nature22815
PMC5626019 28636593

33Lindestam Arlehamn CS , Dhanwani R , Pham J , et al. α‐Synuclein‐specific T cell reactivity is associated with preclinical and early Parkinson's disease . Nat Commun . 2020 ;11 (1 ):1875 . doi:10.1038/s41467-020-15626-w
PMC7171193 32313102

34Boskovic P , Gao W , Kipnis J . Will cellular immunotherapies end neurodegenerative diseases . Trends Immunol . 2024 ;45 (5 ):329 ‐337 . doi:10.1016/j.it.2024.03.006
PMC12013965 38600001

35Da Mesquita S , Papadopoulos Z , Dykstra T , et al. Meningeal lymphatics affect microglia responses and anti‐Aβ immunotherapy . Nature . 2021 ;593 (7858 ):255 ‐260 . doi:10.1038/s41586-021-03489-0
PMC8817786 33911285

36Aspelund A , Antila S , Proulx ST , et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules . J Exp Med . 2015 ;212 (7 ):991 ‐999 . doi:10.1084/jem.20142290
PMC4493418 26077718

37Cugurra A , Mamuladze T , Rustenhoven J , et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma . Science . 2021 ;373 (6553 ): eabf7844. doi:10.1126/science.abf7844
PMC8863069 34083447

38Rustenhoven J , Drieu A , Mamuladze T , et al. Functional characterization of the dural sinuses as a neuroimmune interface . Cell . 2021 ;184 (4 ):1000 ‐1016 . doi:10.1016/j.cell.2020.12.040
PMC8487654 33508229

39Clarkson BD , Walker A , Harris MG , et al. CCR7 deficient inflammatory dendritic cells are retained in the central nervous system . Sci Rep . 2017 ;7 :42856. doi:10.1038/srep42856
PMC5316931 28216674

40Chi H , Pepper M , Thomas PG . Principles and therapeutic applications of adaptive immunity . Cell . 2024 ;187 (9 ):2052 ‐2078 . doi:10.1016/j.cell.2024.03.037
PMC11177542 38670065

41Louveau A , Herz J , Alme MN , et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature . Nat Neurosci . 2018 ;21 (10 ):1380 ‐1391 . doi:10.1038/s41593-018-0227-9
PMC6214619 30224810

42Nauen DW , Troncoso JC . Amyloid‐beta is present in human lymph nodes and greatly enriched in those of the cervical region . Alzheimers Dement . 2022 ;18 (2 ):205 ‐210 . doi:10.1002/alz.12385
34057798

43Merlini M , Kirabali T , Kulic L , Nitsch RM , Ferretti MT . Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study . Neurodegener Dis . 2018 ;18 (1 ):49 ‐56 . doi:10.1159/000486200
29402847

44Togo T , Akiyama H , Iseki E , et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases . J Neuroimmunol . 2002 ;124 (1‐2 ):83 ‐92 . doi:10.1016/s0165-5728(01)00496-9
11958825

45Forner S , Kawauchi S , Balderrama‐Gutierrez G , et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer's disease . Sci Data . 2021 ;8 (1 ):270 . doi:10.1038/s41597-021-01054-y
PMC8519958 34654824

46Gate D , Saligrama N , Leventhal O , et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease . Nature . 2020 ;577 (7790 ):399 ‐404 . doi:10.1038/s41586-019-1895-7
PMC7445078 31915375

47van Olst L , Simonton B , Edwards AJ , et al. Microglial mechanisms drive amyloid‐beta clearance in immunized patients with Alzheimer's disease . Nat Med . 2025 ;31 (5 ):1604 ‐1616 . doi:10.1038/s41591-025-03574-1
PMC12092304 40050704

48Jorfi M , Maaser‐Hecker A , Tanzi RE . The neuroimmune axis of Alzheimer's disease . Genome Med . 2023 ;15 (1 ):6 . doi:10.1186/s13073-023-01155-w PMC9878767 36703235

49Park J‐C , Noh J , Jang S , et al. Association of B cell profile and receptor repertoire with the progression of Alzheimer's disease . Cell Rep . 2022 ;40 (12 ):111391. doi:10.1016/j.celrep.2022.111391
36130492

50Braak H , Braak E . Neuropathological stageing of Alzheimer‐related changes . Acta Neuropathol . 1991 ;82 (4 ):239 ‐259 . doi:10.1007/BF00308809
1759558

51Chen X , Firulyova M , Manis M , et al. Microglia‐mediated T cell infiltration drives neurodegeneration in tauopathy . Nature . 2023 ;615 (7953 ):668 ‐677 . doi:10.1038/s41586-023-05788-0
PMC10258627 36890231

52Chen X , Holtzman DM , Colonna M . Immunity in Alzheimer's disease: from mechanisms to therapies . Immunity . 2026 ;59 (3 ):524 ‐541 . doi:10.1016/j.immuni.2026.02.004
41759511

53Zotova E , Bharambe V , Cheaveau M , et al. Inflammatory components in human Alzheimer's disease and after active amyloid‐β42 immunization . Brain . 2013 ;136 (Pt 9 ):2677 ‐2696 . doi:10.1093/brain/awt210
23943781

54Rickenbach C , Mallone A , Häusle L , et al. Altered T‐cell reactivity in the early stages of Alzheimer's disease . Brain . 2025 ;148 (9 ):3364 ‐3378 . doi:10.1093/brain/awaf167
PMC12404719 40320887

55Monsonego A , Zota V , Karni A , et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease . J Clin Invest . 2003 ;112 (3 ):415 ‐422 . doi:10.1172/JCI18104
PMC166296 12897209

56Bach JP , Dodel R . Naturally occurring autoantibodies against β‐Amyloid . Adv Exp Med Biol . 2012 ;750 :91 ‐99 . doi:10.1007/978-1-4614-3461-0_7
22903668

57Brioschi S , Wang W‐Le , Peng V , et al. Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders . Science . 2021 ;373 (6553 ):eabf9277. doi:10.1126/science.abf9277
PMC8448524 34083450

58Imabayashi K , Yada Y , Kawata K , et al. Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age‐associated B cells in aging and autoimmunity . Sci Adv . 2025 ;11 (16 ):eadt8199. doi:10.1126/sciadv.adt8199
PMC12007576 40249819

59Sarlus H , Heneka MT . Microglia in Alzheimer's disease . J Clin Invest . 2017 ;127 (9 ):3240 ‐3249 . doi:10.1172/JCI90606
PMC5669553 28862638

60Jonsson T , Stefansson H , Steinberg S , et al. Variant of TREM2 associated with the risk of Alzheimer's disease . N Engl J Med . 2013 ;368 (2 ):107 ‐116 . doi:10.1056/NEJMoa1211103
PMC3677583 23150908

61Chen Y , Colonna M . Spontaneous and induced adaptive immune responses in Alzheimer's disease: new insights into old observations . Curr Opin Immunol . Aug 2022 ;77 :102233. doi:10.1016/j.coi.2022.102233 35839620

62Kaya T , Mattugini N , Liu Lu , et al. CD8+ T cells induce interferon‐responsive oligodendrocytes and microglia in white matter aging . Nat Neurosci . 2022 ;25 (11 ):1446 ‐1457 . doi:10.1038/s41593-022-01183-6
PMC9630119 36280798

63Kann O , Almouhanna F , Chausse B . Interferon γ: a master cytokine in microglia‐mediated neural network dysfunction and neurodegeneration . Trends Neurosci . 2022 ;45 (12 ):913 ‐927 . doi:10.1016/j.tins.2022.10.007
36283867

64Dionisio‐Santos DA , Olschowka JA , O'Banion MK . Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease . J Neuroinflammation . 2019 ;16 (1 ):74 . doi:10.1186/s12974-019-1453-0 PMC6449993 30953557

65AmeliMojarad M , AmeliMojarad M . The neuroinflammatory role of microglia in Alzheimer's disease and their associated therapeutic targets . CNS Neurosci Ther . 2024 ;30 (7 ): e14856. doi:10.1111/cns.14856 PMC11259573 39031970

66Brigas HC , Ribeiro M , Coelho JE , et al. IL‐17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease . Cell Rep . 2021 ;36 (9 ):109574. doi:10.1016/j.celrep.2021.109574
34469732

67Bellenguez C , Küçükali F , Jansen IE , et al. New insights into the genetic etiology of Alzheimer's disease and related dementias . Nat Genet . 2022 ;54 (4 ):412 ‐436 . doi:10.1038/s41588-022-01024-z
PMC9005347 35379992

68Kunkle BW , Grenier‐Boley B , Sims R , et al. Genetic meta‐analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing . Nat Genet . 2019 ;51 (3 ):414 ‐430 . doi:10.1038/s41588-019-0358-2
PMC6463297 30820047

69Le Guen Y , Luo G , Ambati A , et al. Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA‐DRB1*04 subtypes . Proc Natl Acad Sci U S A . 2023 ;120 (36 ):e2302720120. doi:10.1073/pnas.2302720120
PMC10483635 37643212

70Kloske CM , Barnum CJ , Batista AF , et al. APOE and immunity: research highlights . Alzheimers Dement . 2023 ;19 (6 ):2677 ‐2696 . doi:10.1002/alz.13020
PMC13158998 36975090

71Krasemann S , Madore C , Cialic R , et al. The TREM2‐APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases . Immunity . 2017 ;47 (3 ):566 ‐581 . doi:10.1016/j.immuni.2017.08.008
PMC5719893 28930663

72Rosenzweig N , Kleemann KL , Rust T , et al. Sex‐dependent APOE4 neutrophil‐microglia interactions drive cognitive impairment in Alzheimer's disease . Nat Med . 2024 ;30 (10 ):2990 ‐3003 . doi:10.1038/s41591-024-03122-3
PMC12952287 38961225

73Li X , Li Z , Chen H , et al. Unraveling APOE4: the dual role in CNS and peripheral inflammation in Alzheimer's disease . Int Immunopharmacol . 2025 ;163 :115199. doi:10.1016/j.intimp.2025.115199
40652586

74Huang K‐L , Marcora E , Pimenova AA , et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease . Nat Neurosci . 2017 ;20 (8 ):1052 ‐1061 . doi:10.1038/nn.4587
PMC5759334 28628103

75Harold D , Abraham R , Hollingworth P , et al. Genome‐wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease . Nat Genet . 2009 ;41 (10 ):1088 ‐1093 . doi:10.1038/ng.440
PMC2845877 19734902

76Lambert J‐C , Ibrahim‐Verbaas CA , Harold D , et al. Meta‐analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease . Nat Genet . 2013 ;45 (12 ):1452 ‐1458 . doi:10.1038/ng.2802
PMC3896259 24162737

77Schwartzentruber J , Cooper S , Liu JZ , et al. Genome‐wide meta‐analysis, fine‐mapping and integrative prioritization implicate new Alzheimer's disease risk genes . Nat Genet . 2021 ;53 (3 ):392 ‐402 . doi:10.1038/s41588-020-00776-w
PMC7610386 33589840

78Sims R , van der Lee SJ , Naj AC , et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial‐mediated innate immunity in Alzheimer's disease . Nat Genet . 2017 ;49 (9 ):1373 ‐1384 . doi:10.1038/ng.3916
PMC5669039 28714976

79Tsai AP , Dong C , Lin PB‐C , et al. Genetic variants of phospholipase C‐γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer's disease . Immunity . 2023 ;56 (9 ):2121 ‐2136.e6 . doi:10.1016/j.immuni.2023.08.008
PMC10564391 37659412

80Hirayasu K , Arase H . Functional and genetic diversity of leukocyte immunoglobulin‐like receptor and implication for disease associations . J Hum Genet . 2015 ;60 (11 ):703 ‐708 . doi:10.1038/jhg.2015.64
26040207

81Hou J , Chen Y , Cai Z , et al. Antibody‐mediated targeting of human microglial leukocyte Ig‐like receptor B4 attenuates amyloid pathology in a mouse model . Sci Transl Med . 2024 ;16 (741 ): eadj9052. doi:10.1126/scitranslmed.adj9052
PMC11977387 38569016

82Kim T , Vidal GS , Djurisic M , et al. Human LilrB2 is a β‐amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model . Science . 2013 ;341 (6152 ):1399 ‐1404 . doi:10.1126/science.1242077
PMC3853120 24052308

83Liu T , Zhang L , Joo D , Sun SC . NF‐κB signaling in inflammation . Signal Transduct Target Ther . 2017 ;2 :17023. doi:10.1038/sigtrans.2017.23 PMC5661633 29158945

84Panyard DJ , Reus LM , Ali M , et al. Post‐GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3 . Alzheimers Dement . 2024 ;20 (7 ):5044 ‐5053 . doi:10.1002/alz.13848
PMC11247664 38809917

85Zhai Y , Celis‐Gutierrez J , Voisinne G , et al. Opposing regulatory functions of the TIM3 (HAVCR2) signalosome in primary effector T cells as revealed by quantitative interactomics . Cell Mol Immunol . 2021 ;18 (6 ):1581 ‐1583 . doi:10.1038/s41423-020-00575-7
PMC8167182 33139903

86Crehan H , Holton P , Wray S , Pocock J , Guerreiro R , Hardy J . Complement receptor 1 (CR1) and Alzheimer's disease . Immunobiology . 2012 ;217 (2 ):244 ‐250 . doi:10.1016/j.imbio.2011.07.017
21840620

87Granzotto A , Vissel B , Sensi SL . Lost in translation: inconvenient truths on the utility of mouse models in Alzheimer's disease research . Elife . 2024 ;13 : e90633. doi:10.7554/eLife.90633 PMC11434637 39329365

88De Plano LM , Saitta A , Oddo S , Caccamo A . Navigating Alzheimer's disease mouse models: age‐related pathology and cognitive deficits . Biomolecules . 2024 ;14 (11 ):1405. doi:10.3390/biom14111405 PMC11592094 39595581

89García‐Carlos CA , Basurto‐Islas G , Perry G , Mondragón‐Rodríguez S . Meta‐analysis in transgenic Alzheimer's disease mouse models reveals opposite brain network effects of amyloid‐β and phosphorylated tau proteins . J Alzheimers Dis . 2024 ;99 (2 ):595 ‐607 . doi:10.3233/JAD-231365
38669540

90Lin C , Tian Y , Tanzi RE , Jorfi M . Approaches for studying neuroimmune interactions in Alzheimer's disease . Trends Immunol . 2024 ;45 (12 ):971 ‐986 . doi:10.1016/j.it.2024.10.002
PMC11624993 39537528

91Oakley H , Cole SL , Logan S , et al. Intraneuronal beta‐amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation . J Neurosci . 2006 ;26 (40 ):10129 ‐10140 . doi:10.1523/JNEUROSCI.1202-06.2006
PMC6674618 17021169

92Radde R , Bolmont T , Kaeser SA , et al. Abeta42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology . EMBO Rep . 2006 ;7 (9 ):940 ‐946 . doi:10.1038/sj.embor.7400784
PMC1559665 16906128

93Gengler S , Hamilton A , Hölscher C . Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice . PLoS One . 2010 ;5 (3 ):e9764. doi:10.1371/journal.pone.0009764 PMC2842299 20339537

94Rupp NJ , Wegenast‐Braun BM , Radde R , Calhoun ME , Jucker M . Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice . Neurobiol Aging . 2011 ;32 (12 ):2324.e1 ‐2324.e23246 . doi:10.1016/j.neurobiolaging.2010.08.014
20970889

95Jankowsky JL , Fadale DJ , Anderson J , et al. Mutant presenilins specifically elevate the levels of the 42 residue beta‐amyloid peptide in vivo: evidence for augmentation of a 42‐specific gamma secretase . Hum Mol Genet . 2004 ;13 (2 ):159 ‐170 . doi:10.1093/hmg/ddh019
14645205

96Zhang W , Bai M , Xi Ye , et al. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction . Free Radic Biol Med . 2012 ;52 (8 ):1443 ‐1452 . doi:10.1016/j.freeradbiomed.2012.01.023
22342520

97Garcia‐Alloza M , Robbins EM , Zhang‐Nunes SX , et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease . Neurobiol Dis . 2006 ;24 (3 ):516 ‐524 . doi:10.1016/j.nbd.2006.08.017
17029828

98Wang S , Lin B , Lin G , et al. Label‐free multiphoton imaging of β‐amyloid plaques in Alzheimer's disease mouse models . Neurophotonics . 2019 ;6 (4 ):045008. doi:10.1117/1.NPh.6.4.045008
PMC6850002 31737743

99Snellman A , Takkinen JS , López‐Picón FR , et al. Effect of genotype and age on cerebral [18F]FDG uptake varies between transgenic APPSwe‐PS1dE9 and Tg2576 mouse models of Alzheimer's disease . Sci Rep . 2019 ;9 (1 ):5700 . doi:10.1038/s41598-019-42074-4
PMC6450965 30952945

100Kamphuis W , Mamber C , Moeton M , et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease . PLoS One . 2012 ;7 (8 ): e42823. doi:10.1371/journal.pone.0042823
PMC3418292 22912745

101Lin T‐W , Liu Yu‐F , Shih Y‐H , et al. Neurodegeneration in amygdala precedes hippocampus in the APPswe/PS1dE9 mouse model of Alzheimer's disease . Curr Alzheimer Res . 2015 ;12 (10 ):951 ‐963 . doi:10.2174/1567205012666151027124938
26502818

102Minkeviciene R , Ihalainen J , Malm T , et al. Age‐related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild‐type mice . J Neurochem . 2008 ;105 (3 ):584 ‐594 . doi:10.1111/j.1471-4159.2007.05147.x
18042177

103Pedrós I , Petrov D , Allgaier M , et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease . Biochim Biophys Acta . 2014 ;1842 (9 ):1556 ‐1566 . doi:10.1016/j.bbadis.2014.05.025
24887203

104Saito T , Matsuba Y , Mihira N , et al. Single App knock‐in mouse models of Alzheimer's disease . Nat Neurosci . 2014 ;17 (5 ):661 ‐663 . doi:10.1038/nn.3697
24728269

105Latif‐Hernandez A , Sabanov V , Ahmed T , et al. The two faces of synaptic failure in App . Alzheimers Res Ther . 2020 ;12 (1 ):100 . doi:10.1186/s13195-020-00667-6
PMC7445922 32838792

106Nilsson P , Saito T , Saido TC . New mouse model of Alzheimer's . ACS Chem Neurosci . 2014 ;5 (7 ):499 ‐502 . doi:10.1021/cn500105p
PMC4102956 24852598

107Wang S , Ichinomiya T , Savchenko P , et al. Age‐dependent behavioral and metabolic assessment of AppNL−G−F/NL−G−F Knock‐in (KI) Mice . Front Mol Neurosci . 2022 ;15 :909989. doi:10.3389/fnmol.2022.909989
PMC9373872 35966019

108Hutton M , Lendon CL , Rizzu P , et al. Association of missense and 5'‐splice‐site mutations in tau with the inherited dementia FTDP‐17 . Nature . 1998 ;393 (6686 ):702 ‐705 . doi:10.1038/31508
9641683

109Oddo S , Caccamo A , Shepherd JD , et al. Triple‐transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction . Neuron . 2003 ;39 (3 ):409 ‐421 . doi:10.1016/s0896-6273(03)00434-3
12895417

110Manaye KF , Mouton PR , Xu G , et al. Age‐related loss of noradrenergic neurons in the brains of triple transgenic mice . Age . 2013 ;35 (1 ):139 ‐147 . doi:10.1007/s11357-011-9343-0
PMC3543748 22127507

111Clinton LK , Billings LM , Green KN , et al. Age‐dependent sexual dimorphism in cognition and stress response in the 3xTg‐AD mice . Neurobiol Dis . 2007 ;28 (1 ):76 ‐82 . doi:10.1016/j.nbd.2007.06.013
PMC2756084 17659878

112Oddo S , Caccamo A , Smith IF , Green KN , LaFerla FM . A dynamic relationship between intracellular and extracellular pools of Abeta . Am J Pathol . 2006 ;168 (1 ):184 ‐194 . doi:10.2353/ajpath.2006.050593
PMC1592652 16400022

113Stover KR , Campbell MA , Van Winssen CM , Brown RE . Early detection of cognitive deficits in the 3xTg‐AD mouse model of Alzheimer's disease . Behav Brain Res . 2015 ;289 :29 ‐38 . doi:10.1016/j.bbr.2015.04.012
25896362

114Kang S‐J , Kim Y‐H , Nguyen‐Phuong T , et al. Immune cell‐enriched single‐cell RNA sequencing unveils the interplay between infiltrated CD8+ T resident memory cells and choroid plexus epithelial cells in Alzheimer's disease . J Neuroimmunol . 2025 ;398 :578488. doi:10.1016/j.jneuroim.2024.578488
39571412

115Altendorfer B , Unger MS , Poupardin R , et al. Transcriptomic profiling identifies CD8+ T cells in the brain of aged and Alzheimer's disease transgenic mice as tissue‐resident memory T cells . J Immunol . 2022 ;209 (7 ):1272 ‐1285 . doi:10.4049/jimmunol.2100737
PMC9515311 36165202

116St‐Amour I , Bosoi CR , Paré I , et al. Peripheral adaptive immunity of the triple transgenic mouse model of Alzheimer's disease . J Neuroinflammation . 2019 ;16 (1 ):3 . doi:10.1186/s12974-018-1380-5
PMC6320637 30611289

117Movsesyan N , Ghochikyan A , Mkrtichyan M , et al. Reducing AD‐like pathology in 3xTg‐AD mouse model by DNA epitope vaccine—a novel immunotherapeutic strategy . PLoS One . 2008 ;3 (5 ):e2124. doi:10.1371/journal.pone.0002124
PMC2358976 18461171

118Baruch K , Rosenzweig N , Kertser A , et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology . Nat Commun . 2015 ;6 :7967 . doi:10.1038/ncomms8967
PMC4557123 26284939

119Mittal K , Eremenko E , Berner O , et al. CD4 T Cells Induce A Subset of MHCII‐Expressing Microglia that Attenuates Alzheimer Pathology . iScience . 2019 ;16 :298 ‐311 . doi:10.1016/j.isci.2019.05.039
PMC6581663 31203186

120Wyatt‐Johnson SK , Kersey HN , Codocedo JF , et al. Control of the temporal development of Alzheimer's disease pathology by the MR1/MAIT cell axis . J Neuroinflammation . 2023 ;20 (1 ):78 . doi:10.1186/s12974-023-02761-6
PMC10029194 36944969

121Kedia S , Ji H , Feng R , et al. T cell‐mediated microglial activation triggers myelin pathology in a mouse model of amyloidosis . Nat Neurosci . 2024 ;27 (8 ):1468 ‐1474 . doi:10.1038/s41593-024-01682-8
PMC11303250 38937583

122Dansokho C , Ait Ahmed D , Aid S , et al. Regulatory T cells delay disease progression in Alzheimer‐like pathology . Brain . 2016 ;139 (Pt 4 ):1237 ‐1251 . doi:10.1093/brain/awv408
26912648

123Hao W , Luo Q , Tomic I , et al. Modulation of Alzheimer's disease brain pathology in mice by gut bacterial depletion: the role of IL‐17a . Gut Microbes . 2024 ;16 (1 ):2363014. doi:10.1080/19490976.2024.2363014
PMC11195493 38904096

124Baligács N , Albertini G , Borrie SC , et al. Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer's Disease . Nat Commun . 2024 ;15 (1 ):10634. doi:10.1038/s41467-024-54779-w
PMC11621353 39639016

125Gustavsson A , Norton N , Fast T , et al. Global estimates on the number of persons across the Alzheimer's disease continuum . Alzheimers Dement . 2023 ;19 (2 ):658 ‐670 . doi:10.1002/alz.12694
35652476

126Dunn SE , Perry WA , Klein SL . Mechanisms and consequences of sex differences in immune responses . Nat Rev Nephrol . 2024 ;20 (1 ):37 ‐55 . doi:10.1038/s41581-023-00787-w
37993681

127Bynoe MS , Grimaldi CM , Diamond B . Estrogen up‐regulates Bcl‐2 and blocks tolerance induction of naive B cells . Proc Natl Acad Sci U S A . 2000 ;97 (6 ):2703 ‐2708 . doi:10.1073/pnas.040577497
PMC15993 10694576

128Peckham H , Radziszewska A , Sikora J , et al. Estrogen influences class‐switched memory B cell frequency only in humans with two X chromosomes . J Exp Med . 2025 ;222 (4 ): e20241253. doi:10.1084/jem.20241253
PMC11893172 40049222

129Chen Z , Balachandran YL , Chong WP , Chan KWY . Roles of Cytokines in Alzheimer's Disease . Int J Mol Sci . 2024 ;25 (11 ): 5803 . doi:10.3390/ijms25115803 PMC11171747 38891990

130Dong W , Peng Q , Liu Z , et al. Estrogen plays an important role by influencing the NLRP3 inflammasome . Biomed Pharmacother . 2023 ;167 :115554. doi:10.1016/j.biopha.2023.115554
37738797

131McCarthy M , Raval AP . The peri‐menopause in a woman's life: a systemic inflammatory phase that enables later neurodegenerative disease . J Neuroinflammation . 2020 ;17 (1 ):317 . doi:10.1186/s12974-020-01998-9 PMC7585188 33097048

132Xu H , Wang R , Zhang YW , Zhang X . Estrogen, beta‐amyloid metabolism/trafficking, and Alzheimer's disease . Ann N Y Acad Sci . 2006 ;1089 :324 ‐342 . doi:10.1196/annals.1386.036
17261779

133Vegeto E , Benedusi V , Maggi A . Estrogen anti‐inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases . Front Neuroendocrinol . 2008 ;29 (4 ):507 ‐519 . doi:10.1016/j.yfrne.2008.04.001
PMC2630539 18522863

134Scheyer O , Rahman A , Hristov H , et al. Female sex and Alzheimer's risk: the menopause connection . J Prev Alzheimers Dis . 2018 ;5 (4 ):225 ‐230 . doi:10.14283/jpad.2018.34
PMC6198681 30298180

135Averyanova M , Yureneva S , Kiseleva V , et al. Effect of menopausal hormone therapy on cellular immunity parameters and cytokine profile . Biomedicines . 2024 ;12 (8 ): 1892 . doi:10.3390/biomedicines12081892
PMC11351925 39200355

136Chakraborty B , Byemerwa J , Krebs T , Lim F , Chang CY , McDonnell DP . Estrogen Receptor Signaling in the Immune System . Endocr Rev . 2023 ;44 (1 ):117 ‐141 . doi:10.1210/endrev/bnac017
35709009

137Kamada M , Irahara M , Maegawa M , et al. B cell subsets in postmenopausal women and the effect of hormone replacement therapy . Maturitas . 2001 ;37 (3 ):173 ‐179 . doi:10.1016/s0378-5122(00)00180-8
11173179

138Miller VT . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial . JAMA . 1995 ;273 (3 ):199 ‐208 . doi:10.1001/jama.1995.03520270033028
7807658

139Lakoski SG , Herrington DM . Effects of hormone therapy on C‐reactive protein and IL‐6 in postmenopausal women: a review article . Climacteric . 2005 ;8 (4 ):317 ‐326 . doi:10.1080/13697130500345109
16390766

140Casanova G , Spritzer PM . Effects of micronized progesterone added to non‐oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial . Lipids Health Dis . 2012 ;11 :133. doi:10.1186/1476-511X-11-133 PMC3508911 23046709

141Grimaldi CM , Michael DJ , Diamond B . Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen‐induced lupus . J Immunol . 2001 ;167 (4 ):1886 ‐1890 . doi:10.4049/jimmunol.167.4.1886
11489967

142Grimaldi CM , Cleary J , Dagtas AS , Moussai D , Diamond B . Estrogen alters thresholds for B cell apoptosis and activation . J Clin Invest . 2002 ;109 (12 ):1625 ‐1633 . doi:10.1172/JCI14873
PMC151010 12070310

143Medina KL , Strasser A , Kincade PW . Estrogen influences the differentiation, proliferation, and survival of early B‐lineage precursors . Blood . 2000 ;95 (6 ):2059 ‐2067 . doi:10.1182/blood.V95.6.2059
10706875

144Lee JH , Ulrich B , Cho J , Park J , Kim CH . Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells . J Immunol . 2011 ;187 (4 ):1778 ‐1787 . doi:10.4049/jimmunol.1003919
PMC3155957 21768398

145Lissauer D , Eldershaw SA , Inman CF , Coomarasamy A , Moss PA , Kilby MD . Progesterone promotes maternal‐fetal tolerance by reducing human maternal T‐cell polyfunctionality and inducing a specific cytokine profile . Eur J Immunol . 2015 ;45 (10 ):2858 ‐2872 . doi:10.1002/eji.201445404
PMC4833190 26249148

146Shifren JL , Rifai N , Desindes S , McIlwain M , Doros G , Mazer NA . A comparison of the short‐term effects of oral conjugated equine estrogens versus transdermal estradiol on C‐reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women . J Clin Endocrinol Metab . 2008 ;93 (5 ):1702 ‐1710 . doi:10.1210/jc.2007-2193
18303079

147Vongpatanasin W , Tuncel M , Wang Z , Arbique D , Mehrad B , Jialal I . Differential effects of oral versus transdermal estrogen replacement therapy on C‐reactive protein in postmenopausal women . J Am Coll Cardiol . 2003 ;41 (8 ):1358 ‐1363 . doi:10.1016/s0735-1097(03)00156-6
12706932

148Komane M , Avenant C , Louw‐du Toit R , Africander DJ , Hapgood JP . Differential off‐target glucocorticoid activity of progestins used in endocrine therapy . Steroids . 2022 ;182 :108998. doi:10.1016/j.steroids.2022.108998 PMC9081821 35271867

149Maki PM , Henderson VW . Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on . Climacteric . 2012 ;15 (3 ):256 ‐262 . doi:10.3109/13697137.2012.660613
PMC3667708 22612612

150Nerattini M , Jett S , Andy C , et al. Systematic review and meta‐analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia . Front Aging Neurosci . 2023 ;15 :1260427. doi:10.3389/fnagi.2023.1260427
PMC10625913 37937120

151Xu Li , Dong B , Wang H , et al. Progesterone suppresses Th17 cell responses, and enhances the development of regulatory T cells, through thymic stromal lymphopoietin‐dependent mechanisms in experimental gonococcal genital tract infection . Microbes Infect . 2013 ;15 (12 ):796 ‐805 . doi:10.1016/j.micinf.2013.06.012
23835188

152Yang JL , Hodara E , Sriprasert I , Shoupe D , Stanczyk FZ . Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials . Menopause . 2024 ;31 (10 ):926 ‐939 . doi:10.1097/GME.0000000000002407
PMC12072814 39081162

153Illouz T , Biragyn A , Iulita MF , et al. Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with down syndrome . Front Immunol . 2021 ;12 :621440. doi:10.3389/fimmu.2021.621440
PMC8267813 34248930

154Jack CR , Andrews JS , Beach TG , et al. Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup . Alzheimers Dement . 2024 ;20 (8 ):5143 ‐5169 . doi:10.1002/alz.13859
PMC11350039 38934362

155Sukreet S , Rafii MS , Rissman RA . From understanding to action: exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach . Alzheimers Dement . 2024 ;16 (2 ):e12580. doi:10.1002/dad2.12580 PMC11016820 38623383

156Barroeta I , Videla L , Carmona‐Iragui M , Fortea J , Rafii MS . Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: navigating new therapeutic frontiers . Alzheimers Dement . 2025 ;21 (6 ):e70258. doi:10.1002/alz.70258 PMC12173829 40528298

157Saini F , Dell'Acqua F , Strydom A . Structural Connectivity in Down Syndrome and Alzheimer's Disease . Front Neurosci . 2022 ;16 :908413. doi:10.3389/fnins.2022.908413 PMC9354601 35937882

158Gensous N , Bacalini MG , Franceschi C , Garagnani P . Down syndrome, accelerated aging and immunosenescence . Semin Immunopathol . 2020 ;42 (5 ):635 ‐645 . doi:10.1007/s00281-020-00804-1
PMC7666319 32705346

159Sanford SAI , McEwan WA . Type‐I Interferons in Alzheimer's Disease and Other Tauopathies . Front Cell Neurosci . 2022 ;16 :949340. doi:10.3389/fncel.2022.949340 PMC9334774 35910253

160Lopez‐Atalaya JP , Bhojwani‐Cabrera AM . Type I interferon signalling and interferon‐responsive microglia in health and disease . FEBS J . 2025 ;292 (22 ):5921 ‐5940 . doi:10.1111/febs.70126
PMC12631166 40299722

161Groh J , Feng R , Yuan X , et al. Microglia activation orchestrates CXCL10‐mediated CD8 . Nat Neurosci . 2025 ;28 (6 ):1160 ‐1173 . doi:10.1038/s41593-025-01955-w
PMC12148934 40404995

162Dubois B , Villain N , Schneider L , et al. Alzheimer disease as a clinical‐biological construct‐an international working group recommendation . JAMA Neurol . 2024 ;81 (12 ):1304 ‐1311 . doi:10.1001/jamaneurol.2024.3770
PMC12010406 39483064

163Rovelet‐Lecrux A , Hannequin D , Raux G , et al. APP locus duplication causes autosomal dominant early‐onset Alzheimer disease with cerebral amyloid angiopathy . Nat Genet . 2006 ;38 (1 ):24 ‐26 . doi:10.1038/ng1718
16369530

164Sleegers K , Brouwers N , Gijselinck I , et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy . Brain . 2006 ;129 (Pt 11 ):2977 ‐2983 . doi:10.1093/brain/awl203
16921174

165Waugh KA , Minter R , Baxter J , et al. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model . Nat Genet . 2023 ;55 (6 ):1034 ‐1047 . doi:10.1038/s41588-023-01399-7
PMC10260402 37277650

166Heneka MT , Morgan D , Jessen F . Passive anti‐amyloid β immunotherapy in Alzheimer's disease‐opportunities and challenges . Lancet . 2024 ;404 (10468 ):2198 ‐2208 . doi:10.1016/S0140-6736(24)01883-X
39549715

167Eyting M , Xie M , Michalik F , Heß S , Chung S , Geldsetzer P . A natural experiment on the effect of herpes zoster vaccination on dementia . Nature . 2025 ;641 (8062 ):438 ‐446 . doi:10.1038/s41586-025-08800-x
PMC12058522 40175543

168Liu Yu‐H , Wang J , Li Q‐X , et al. Association of naturally occurring antibodies to β‐amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease . Sci Adv . 2021 ;7 (1 ):eabb0457. doi:10.1126/sciadv.abb0457
PMC7775771 33523832

169Holmes C , Boche D , Wilkinson D , et al. Long‐term effects of Abeta42 immunisation in Alzheimer's disease: follow‐up of a randomised, placebo‐controlled phase I trial . Lancet . 2008 ;372 (9634 ):216 ‐223 . doi:10.1016/S0140-6736(08)61075-2
18640458

170Pascual‐Lucas M , Lacosta AM , Montañés M , et al. Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: a randomized, double‐blind, placebo‐controlled phase 2 study . Alzheimers Dement . 2025 ;21 (10 ):e70776. doi:10.1002/alz.70776
PMC12504058 41058018

171Kovacech B , Cullen NC , Novak P , et al. Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p‐tau217 . Alzheimers Res Ther . 2024 ;16 (1 ):254 . doi:10.1186/s13195-024-01620-7
PMC11585249 39580468

172Sol O , Mermoud J , Hallikainen M , et al. Safety and immunogenicity of two Tau‐targeting active immunotherapies, ACI‐35.030 and JACI‐35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double‐blind, randomised, placebo‐controlled study . EBioMedicine . 2025 ;120 :105940. doi:10.1016/j.ebiom.2025.105940
PMC12481106 40972226

173Budd Haeberlein S , Aisen PS , Barkhof F , et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease . J Prev Alzheimers Dis . 2022 ;9 (2 ):197 ‐210 . doi:10.14283/jpad.2022.30
35542991

174van Dyck CH , et al. Lecanemab in Early Alzheimer's Disease . N Engl J Med . 2023 ;388 (1 ):9 ‐21 . doi:10.1056/NEJMoa2212948
36449413

175Sims JR , Zimmer JA , Evans CD , et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER‐ALZ 2 randomized clinical trial . JAMA . 2023 ;330 (6 ):512 ‐527 . doi:10.1001/jama.2023.13239
PMC10352931 37459141

176Greenberg SM , Bax F , van Veluw SJ . Amyloid‐related imaging abnormalities: manifestations, metrics and mechanisms . Nat Rev Neurol . 2025 ;21 (4 ):193 ‐203 . doi:10.1038/s41582-024-01053-8
39794509

177Rabinovici GD , Selkoe DJ , Schindler SE , et al. Donanemab: appropriate use recommendations . J Prev Alzheimers Dis . 2025 ;12 (5 ):100150. doi:10.1016/j.tjpad.2025.100150
PMC12180672 40155270

178Su C‐H , Chang Y‐T , Tseng H‐S , et al. Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: a network meta‐analysis of randomised controlled trials . Clin Med . 2025 ;25 (4 ):100336. doi:10.1016/j.clinme.2025.100336
PMC12240074 40473116

179Zimmer JA , Ardayfio P , Wang H , et al. Amyloid‐related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER‐ALZ and ALZ 2 randomized clinical trials . JAMA Neurol . 2025 ;82 (5 ):461 ‐469 . doi:10.1001/jamaneurol.2025.0065
PMC11894547 40063015

180Kulic L , Alcaraz F , Klein G , et al. Latest results from the dose‐expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease . Alzheimers Dement . 2025 ;21 (S5 ):e104293. doi:10.1002/alz70859_104293

181Panza F , Dibello V , Sardone R , et al. Successes and failures: the latest advances in the clinical development of amyloid‐β‐targeting monoclonal antibodies for treating Alzheimer's disease . Expert Opin Biol Ther . 2025 ;25 (3 ):275 ‐283 . doi:10.1080/14712598.2025.2463963
39908579

182Arumugham VB , Rayi A . Intravenous Immunoglobulin (IVIG) . StatPearls Publishing; 2023 .32119333

183Relkin N . Clinical trials of intravenous immunoglobulin for Alzheimer's disease . J Clin Immunol . 2014 34 (Suppl 1 ):S74 ‐S79 . doi:10.1007/s10875-014-0041-4
24760112

184Relkin NR , Thomas RG , Rissman RA , et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease . Neurology . 2017 ;88 (18 ):1768 ‐1775 . doi:10.1212/WNL.0000000000003904
PMC5409846 28381506

185Magga J , Puli L , Pihlaja R , et al. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease . J Neuroinflammation . 2010 ;7 :90. doi:10.1186/1742-2094-7-90
PMC3004875 21138577

186Puli L , Pomeshchik Y , Olas K , Malm T , Koistinaho J , Tanila H . Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease . J Neuroinflammation . 2012 ;9 :105. doi:10.1186/1742-2094-9-105 PMC3416679 22642812

187St‐Amour I , Paré I , Tremblay C , Coulombe K , Bazin R , Calon F . IVIg protects the 3xTg‐AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology . J Neuroinflammation . 2014 ;11 :54. doi:10.1186/1742-2094-11-54 PMC3997966 24655894

188Counts SE , Perez SE , He B , Mufson EJ . Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease . Curr Alzheimer Res . 2014 ;11 (7 ):655 ‐663 . doi:10.2174/1567205011666140812114037
PMC6364843 25156574

189Sudduth TL , Greenstein A , Wilcock DM . Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti‐Aβ antibodies . J Neurosci . 2013 ;33 (23 ):9684 ‐9692 . doi:10.1523/JNEUROSCI.1220-13.2013
PMC3839584 23739965

190Dubey S , Heinen S , Krantic S , et al. Clinically approved IVIg delivered to the hippocampus with focused ultrasound promotes neurogenesis in a model of Alzheimer's disease . Proc Natl Acad Sci U S A . 2020 ;117 (51 ):32691 ‐32700 . doi:10.1073/pnas.1908658117
PMC7768694 33288687

191Nagelkerke SQ , Kuijpers TW . Immunomodulation by IVIg and the Role of Fc‐Gamma Receptors: classic Mechanisms of Action after all? . Front Immunol . 2015 ;5 :674. doi:10.3389/fimmu.2014.00674 PMC4301001 25653650

192Bruhns P . Properties of mouse and human IgG receptors and their contribution to disease models . Blood . 2012 ;119 (24 ):5640 ‐5649 . doi:10.1182/blood-2012-01-380121
22535666

193Fuller JP , Stavenhagen JB , Teeling JL . New roles for Fc receptors in neurodegeneration‐the impact on Immunotherapy for Alzheimer's Disease . Front Neurosci . 2014 ;8 :235. doi:10.3389/fnins.2014.00235 PMC4139653 25191216

194Fernandez‐Vizarra P , Lopez‐Franco O , Mallavia B , et al. Immunoglobulin G Fc receptor deficiency prevents Alzheimer‐like pathology and cognitive impairment in mice . Brain . 2012 ;135 (Pt 9 ):2826 ‐2837 . doi:10.1093/brain/aws195
22961553

195Baruch K , Deczkowska A , Rosenzweig N , et al. PD‐1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease . Nat Med . 2016 ;22 (2 ):135 ‐137 . doi:10.1038/nm.4022
26779813

196Latta‐Mahieu M , Elmer B , Bretteville A , et al. Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models . Glia . 2018 ;66 (3 ):492 ‐504 . doi:10.1002/glia.23260
29134678

197Faridar A , Eid AM , Thome AD , et al. A phase 1 open‐label pilot study of low‐dose interleukine‐2 immunotherapy in patients with Alzheimer's disease . Transl Neurodegener . 2023 ;12 (1 ):54 . doi:10.1186/s40035-023-00387-5
PMC10652426 37968718

198Faridar A , Gamez N , Li D , et al. Low‐dose interleukin‐2 in patients with mild to moderate Alzheimer's disease: a randomized clinical trial . Alzheimers Res Ther . 2025 ;17 (1 ):146 . doi:10.1186/s13195-025-01791-x
PMC12231701 40615880

Come citare questo studio

Sophie Shirenova, Arya Biragyn, Eitan Okun. (2026). Age-linked biological context shapes adaptive immunity in Alzheimer's disease.. Alzheimer's & dementia : the journal of the Alzheimer's Association. DOI: 10.1002/alz.71978

Consulta la pubblicazione originale ↗